As filed with the Securities and Exchange Commission
on June 30, 2017
Registration No. 333-194359
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Post-Effective Amendment No. 2
to
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
JRSIS
HEALTH CARE CORPORATION.
(Exact name of Registrant as specified in its
charter)
Florida
|
|
8099
|
|
46-4562047
|
(State or other jurisdiction of incorporation
or organization)
|
|
(Primary Standard Industrial Classification
Code Number)
|
|
(I.R.S. Employer
Identification Number)
|
1
st
– 7
th
Floor,
Industrial and Commercial Bank Building,
Xingfu Street, Hulan Town, Hulan District,
Harbin City,
Heilongjiang Province, China 150025
(Address, including zip code, and telephone
number, including area code,
of Registrant’s principal executive offices)
William D. O’Neal, Esq.
2686 N. Crestwood Ct.
Florence, AZ 85132
Office: (480) 510-4253
Cell: (480) 409-1146
Email: bdoneal59@gmail.com
(Name, address, including zip code, and
telephone number,
including area code, of agent for service)
Approximate date of commencement of proposed
sale to the public: As soon as practicable after the effective date of this registration statement.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, as amended, please check the following box:
x
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.
¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer
|
¨
|
|
Accelerated filer
|
¨
|
|
|
|
|
|
Non-accelerated filer
|
¨
|
(Do not check if smaller reporting company)
|
Smaller reporting company
|
x
|
The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment
which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section 8(a), may determine.
EXPLANATORY NOTE
This Post-Effective Amendment No. 2 to the Registration Statement
on Form S-1 (File No. 333-194359) of JRSIS Health Care Corporation is being filed pursuant to the undertakings in the Registration
Statement to update and supplement the information contained in the Registration Statement, as originally declared effective by
the SEC on November 12, 2014, to include the information contained in the Company’s annual report on Form 10-K for the fiscal
year ended December 31, 2016 that was filed with the SEC on March 29, 2017, and quarterly report on Form 10Q for the three months
ended March 31, 2017 that was filed with the SEC on May 15, 2017.
The information included in this filing updates and supplements
this Registration Statement and the Prospectus contained therein. No changes have been made to the Prospectus contained in the
Registration Statement (which Prospectus continues to form a part of the Registration Statement. No additional securities are being
registered under this Post-Effective Amendment No. 2. All applicable registration fees were paid at the time of the original filing
of the Registration Statement.
The information in this prospectus is not complete and may be amended. The Issuer may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
|
SUBJECT TO COMPLETION DATED June 30,
2017
RESALE PROSPECTUS
JRSIS
HEALTH CARE CORPORATION.
1,589,000 SHARES OF COMMON STOCK
OFFERING PRICE $0.5725PER SHARE
We are registering for resale 1,589,000 shares of our common stock
by selling stockholders (the "Resale Offering"). The selling stockholders, which identified in this prospectus, they
may sell these shares from time to time in the open market (at the prevailing market price) or in negotiated transactions.
You should read this prospectus and any prospectus supplement carefully
before you invest. We will not receive any proceeds from the sale of shares by the selling stockholders.
Our common stock has been assigned the trading symbol “JRSS”,
and our common stock is trading on The OTCQB Market.
Resale Offering Prospectus
We are registering for resale 1,589,000 shares
of our common stock by selling stockholders (the "Resale Offering"). The selling security holders will offer and sell
our common stock at a fixed price of $0.5725 per share, until a public market emerges for our common stock and, thereafter, at
prevailing market prices.
OUR BUSINESS IS SUBJECT TO MANY RISKS AND
AN INVESTMENT IN OUR COMMON STOCK WILL ALSO INVOLVE A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY CONSIDER THE FACTORS DESCRIBED
UNDER THE HEADING “RISK FACTORS” BEGINNING ON PAGE 6 BEFORE INVESTING IN OUR COMMON STOCK.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF
THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus is June 30, 2017
TABLE OF CONTENTS
This prospectus is part of a registration statement
that we filed with the Securities and Exchange Commission. You should rely only on the information contained in this prospectus
or to which we have referred you. We have not authorized anyone to provide you with information or to make any representation on
behalf of JRSIS HEALTH CARE COROPORATION that is different from that contained in this prospectus. You should not rely on any unauthorized
information or representation. This prospectus is an offer to sell only the securities offered by this prospectus under circumstances
and in jurisdictions where it is lawful to do so. The information in this prospectus is accurate only as of the date of this prospectus,
regardless of the date of delivery of this prospectus or of any sales of these securities. Our business, financial condition, results
of operations and prospects may have changed since the date of this prospectus. This prospectus may be used only in jurisdictions
where it is legal to sell these securities.
PROSPECTUS SUMMARY
This summary highlights certain information
contained elsewhere in this prospectus. You should read the entire prospectus carefully, including our financial statements and
related notes, and especially the risks described under “Risk Factors” beginning on page 6. All references to “we,”
“us,” “our,”, “Company” or similar terms used in this prospectus refer to JRSIS HEALTH CARE
CORPORATION. Unless otherwise indicated, the term “fiscal year” refers to our fiscal year ending December
31. Unless otherwise indicated, the term “common stock” refers to shares of the Company’s common stock.
Overview
Harbin Jiarun Hospital Company Limited (“Jiarun
Hospital”) was established in Harbin in the Province of Heilongjiang of the People’s Republic of China (“PRC”)
by the owner Junsheng Zhang on February 17, 2006.
Jiarun is a private hospital serving patients
on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. Jiarun specializes
in the areas of Pediatrics, Dermatology, ENT, Traditional Chinese Medicine (TCM), Ophthalmology, Internal Medicine Dentistry, General
Surgery, Rehabilitation Science, Gynecology, General Medical Services, etc.
On November 20, 2013, Junsheng Zhang, the officer
of Jiarun Hospital established JRSIS HEALTH CARE CORPORATION, a Florida corporation (“JHCC” or the “Company”).
On February 25, 2013, the officer of Jiarun Hospital established JRSIS HEALTH CARE LIMITED ("JHCL"), a wholly owned subsidiary
of the Company, and On September 17, 2012, the officer of Jiarun Hospital established Runteng Medical Group Co., Ltd (“Runteng”),
a wholly owned subsidiary of JHCL. Runteng, a Hong Kong registered Investment Company, holds a seventy percent (70%) ownership
interest in Harbin Jiarun Hospital Company Ltd, a Heilongjiang registered company.
On December 20, 2013, the Company acquired
One Hundred Percent (100%) of the issued and outstanding capital stock of JRSIS Health Care Limited, a privately held Limited Liability
Company registered in the British Virgin Islands (“JHCL”) for Twelve Million (12,000,000) shares of our common stock.
JHCL, through its wholly owned subsidiary, Runteng Medical Group Co., Ltd (“Runteng”), holds majority ownership in
Harbin Jiarun Hospital Co., Ltd, a company duly incorporated, organized and validly existing under the laws of China (“Jiarun”).
As the parent company, JHCC rely on Jiarun Hospital to conduct One Hundred Percent (100%) of our businesses and operations.
We have two sources of patient revenues: in-patient
service revenues and out-patient service revenues. In addition to provide services to our patients, we also sell pharmaceutical
medicines to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service
revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers,
under which the hospital is paid based upon local government established charges. Revenue from the sale of medicine is recognized
when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine,
ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all
of which generally occur when the patient receives the medicine. Patient service revenue is recognized when it is both earned and
realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the
patient and collection of the revenue is reasonably assured.
All of the shares covered by this prospectus
are being offered for resale by the selling stockholder named in this prospectus. We will not receive any proceeds from the sale
of the shares.
An investment in our common stock is speculative
and involves substantial risks. You should read the “Risk Factors” section of this prospectus for a discussion of certain
factors to consider carefully before deciding to invest in shares of our common stock.
Recent Developments
We have incorporated by reference into this prospectus our annual
report on Form 10-K for the fiscal year ended December 31, 2014 that was filed with the SEC on March 31, 2015, and quarterly report
on Form 10-Q for the three, six and nine months ended September 30, 2015 that was filed with the SEC on November 16, 2015, and
the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2015 that was filed with the SEC on March
29, 2016, and quarterly report on Form 10-Q for the three, six and nine months ended September 30, 2016 that was filed with the
SEC on November 14, 2016, and the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2016 that was
filed with the SEC on March 29, 2017.
The information incorporated by reference to this prospectus supplement
updates and supplements JRSIS HEALTH CARE CORPORATION’s Registration Statement declared effective on November 12. 2014.
Our common stock has been assigned the trading
symbol “JRSS”, and our common stock is trading on The OTCQB Market.
Summary of the Offering
Shares of common stock offered by us:
|
|
None.
|
Shares of common stock offered by Selling Stockholder:
|
|
1,589,000 shares of our common stock.
|
|
|
|
Use of Proceeds:
|
|
We will not receive any proceeds from the sale of common stock offering by the selling stockholders covered by this prospectus.
|
|
|
|
Risk Factors:
|
|
An investment in our common stock is speculative and involves substantial
risks. You should read the “Risk Factors” section of this prospectus for a discussion of certain factors to consider
carefully before deciding to invest in shares of our common stock.
|
Plan of Distribution:
|
|
The shares of common stock covered by this prospectus may be sold
by the selling stockholder in the manner described under “Plan of Distribution.”
|
Trading Symbol:
|
|
“JRSS”
|
RISK FACTORS
An investment in our common stock involves
a high degree of risk. You should carefully consider the following risk factors and other information in this prospectus before
deciding to invest in our common stock. If any of the following risks actually occur, our business, financial condition, results
of operations and prospects for growth could be seriously harmed. As a result, the trading price of our common stock could decline
and you could lose all or part of your investment.
Risks Related to Our Business
If we fail to properly manage the employment
of our doctors and nurses, we may be subject to penalties including fines, loss of licenses, or an order to cease practice against
our medical centers, which could materially and adversely affect our business.
The practicing activities of doctors and nurses
are strictly regulated under the PRC laws and regulations. Doctors and nurses who practice at medical institutions must hold practicing
licenses and may only practice within the scope and at the specific medical institutions for which their practicing licenses are
registered.
In practice, it usually takes four to nine
weeks for doctors and nurses to transfer their practicing licenses from one medical institution to another or add another medical
institution to their permitted practicing institutions. Some of our recently hired doctors have submitted applications to transfer
their practicing licenses from their previous employers to our medical centers but have not finished the process. We cannot assure
you that these doctors will complete the transfer of their practicing licenses or the government procedures timely, or at all.
Our failure to properly manage the employment of our doctors and nurses may subject us to administrative penalties including fines,
loss of licenses, or, in the worst-case scenario, an order to cease practice against our medical centers, which could materially
and adversely affect our business.
Our business exposes us to liability
risks that are inherent in the operation of complex medical equipment, which may experience failures or cause injury either because
of defects, faulty maintenance or repair, or improper use.
Our business exposes us to liability risks
that are inherent in the operation of complex medical equipment, which may experience failures or cause injury either because of
defects, faulty maintenance or repair, or improper use. Extended downtime of our medical equipment could result in lost revenues,
dissatisfaction on the part of customers and damage to our reputation. Any injury caused by our medical equipment in our medical
centers due to equipment defects, improper maintenance or improper operation could subject us to liability claims. Regardless of
their merit or eventual outcome, such liability claims could result in significant legal defense costs for us, harm our reputation,
and otherwise have a material adverse effect on our business, financial condition and results of operations.
We primarily rely on equipment manufacturers
or third-party service providers to maintain and repair the complex medical equipment used in our medical centers. If any of these
manufacturers or third-party service providers fails to perform its contractual obligations to provide such services, or refuses
to renew these service agreements on terms acceptable to us, or at all, we may not be able to find a suitable alternative service
provider or establish our own maintenance and repair team in a timely manner. Similarly, any failure of or significant quality
deterioration in such service providers’ services could materially and adversely affect customer experience. We also rely
on both equipment manufacturers and our own internal expertise to provide technical training to our staff on the proper operation
of such equipment. If such medical technicians are not properly and adequately trained, or if they make errors in the operation
of the complex medical equipment even if they are properly trained, they may misuse or ineffectively use the complex medical equipment
in our medical centers. Such failure could result in unsatisfactory medical examination results, diagnosis, treatment outcomes,
patient injury or possibly death, any of which could materially and adversely affect our business, financial condition, results
of operations and prospects.
Financial projections included with this Registration Statement
may prove to be inaccurate.
Any projections are based on certain assumptions
which could prove to inaccurate and which would be subject to future conditions, which may be beyond our control, such as general
industry conditions. We may experience unanticipated costs, or anticipated revenues may not materialize, resulting in lower operating
results than forecasted. We cannot assure that the results illustrated in any financial projections will in fact be realized by
us. Any financial projections would be prepared by our management and would not be examined or compiled by independent certified
public accountants. Counsel to us has had no participation in the preparation or review of any financial projections prepared by
us. Accordingly, neither the independent certified public accountants nor our counsel would be able to provide any level of assurance
on them. We cannot assure that we will have sufficient capital to expand our business operations. We cannot assure that we could
obtain additional financing or capital from any source, or that such financing or capital would be available to us on terms acceptable
to us.
We may not be able to compete against companies with substantially
greater resources.
The hospital industry is intensely competitive
and we expect competition to intensify further in the future. This is a very capital-intensive business and companies with greater
resources may have advantages that make our model weaker in comparison.
Our business is subject to various government regulations.
We are subject to various federal, state and
local laws affecting medical products in China. The State Food and Drug Administration (“SFDA”), Ministry of Health
of The People’s Republic of China (“MoHPRC”) and equivalent state agencies regulate healthcare services made
by businesses in the offering of service, which apply to us. We are also subject to government laws and regulations governing health,
safety, working conditions, employee relations, wrongful termination, wages, taxes and other matters applicable to businesses in
general. Any such new regulation, or the application of laws or regulations from jurisdictions whose laws do not currently apply
to our business, could have a material adverse effect on our business, results of operations, and financial condition.
We cannot assure that we will earn a
profit or that our products will be accepted by consumers.
Our business is speculative and reliant on
acceptance of our brand name by local communities, physicians, patients and advertisers. Our operating performance is also heavily
dependent on our ability to earn a profit from our services. We cannot assure as to whether we will be successful or earn any revenue
or profit, or that investors will not lose their entire investment.
We may incur uninsured losses.
Although we maintain vehicle insurance and basic Chinese social
insurances and related insurance, we cannot assure that we will not incur uninsured liabilities and losses as a result of the conduct
of our business. Should uninsured losses occur, the holders of our common stock and debt could lose their invested capital.
Like most providers of medical services, we are subject to
potential litigation.
We are exposed to the risk of litigation for
a variety of reasons, including service liability lawsuits, employee lawsuits, commercial contract disputes, government enforcement
actions, and other legal proceedings. We cannot assure that future litigation in which we may become involved will not have a material
adverse effect on our financial condition, operating results, business performance, and business reputation.
We do not maintain any business liability insurance,
insurance companies in China offer limited business insurance products. While business liability insurance is available to a limited
extent in China, we have determined that the risks, cost of such insurance and the difficulties associated with acquiring such
insurance on commercially reasonable terms make it impractical for us to purchase such insurance. Product or medical malpractice
liability or uninsured damage to any of our medical centers or the medical equipment in our medical centers could result in significant
disruption to the operation of our medical centers and result in a material adverse effect to our business, financial condition
and results of operations.
We may incur cost overruns in the distribution of our various
services.
We may incur substantial cost overruns in the
distribution of our services. Unanticipated costs may force us to obtain additional capital or financing from other sources, or
may cause us to lose our entire investment if we are unable to obtain the additional funds necessary to implement our business
plan. We cannot assure that we will be able to obtain sufficient capital to successfully continue the implementation of our business
plan. If a greater investment in the business is required due to cost overruns, the probability of earning a profit or a return
of the Shareholders’ investment in us diminishes.
Directors and officers have limited liability.
Our bylaws provide that we will indemnify and
hold harmless our officers and directors against claims arising from our activities, to the maximum extent permitted by business
laws of the State of Florida. If we were called upon to perform under our indemnification agreement, then the portion of our assets
expended for such purpose would reduce the amount otherwise available for our business. We have no executed indemnification agreement.
If we are unable to hire, retain or motivate qualified personnel,
consultants, independent contractors, and advisors, we may not be able to grow effectively.
Our performance will be largely dependent on
the talents and efforts of highly skilled individuals. Future success depends on our continuing ability to identify, hire, develop,
motivate and retain highly qualified personnel for all areas of our organization. Competition for such qualified employees is intense.
If we do not succeed in attracting excellent personnel or in retaining or motivating them, we may be unable to grow effectively.
In addition, all future success depends largely on our ability to retain key consultants and advisors. We cannot assure that any
skilled individuals will agree to become an employee, consultant, or independent contractor of JRSIS. Our inability to retain their
services could negatively impact our business and our ability to execute our business strategy. From our past experiences, we have
never had difficulties hiring or retaining qualified personnel, independent contractors or advisors.
Risks Related to the Company’s Corporate
Structure
The failure to comply with PRC regulations
relating to mergers and acquisitions of domestic enterprises by offshore special purpose vehicles may subject us to severe fines
or penalties and create other regulatory uncertainties regarding our corporate structure.
On August 8, 2006, the PRC Ministry of Commerce
(“MOFCOM”), joined by the China Securities Regulatory Commission (the “CSRC”), the State-owned Assets Supervision
and Administration Commission of the State Council (the “SASAC”), the State Administration of Taxation (the “SAT”),
the State Administration for Industry and Commerce (the “SAIC”), and the State Administration of Foreign Exchange (“SAFE”),
jointly promulgated regulations entitled the Provisions Regarding Mergers and Acquisitions of Domestic Enterprises by Foreign Investors
(the "M&A Rules"), which took effect as of September 8, 2006. This regulation, among other things, has certain provisions
that require offshore special purpose vehicles (“SPVs”) formed for the purpose of acquiring PRC domestic companies
and controlled directly or indirectly by PRC individuals and companies, to obtain the approval of MOFCOM prior to engaging in such
acquisitions and to obtain the approval of the CSRC prior to publicly listing their securities on an overseas stock market. On
September 21, 2006, the CSRC published on its official website a notice specifying the documents and materials that are required
to be submitted for obtaining CSRC approval.
The application of the M&A Rules with respect
to our corporate structure and to this offering remains unclear, with no current consensus existing among leading PRC law firms
regarding the scope and applicability of the M&A Rules. We believe that the MOFCOM and CSRC approvals under the M&A Rules
were not required in the context of our share exchange transaction because at such time the share exchange was a foreign related
transaction governed by foreign laws, not subject to the jurisdiction of PRC laws and regulations. However, we cannot be certain
that the relevant PRC government agencies, including the CSRC and MOFCOM, would reach the same conclusion, and we cannot be certain
that MOFCOM or the CSRC may deem that the transactions effected by the share exchange circumvented the M&A Rules, and other
rules and notices, and that prior MOFCOM or CSRC approval is required for this offering. Further, we cannot rule out the possibility
that the relevant PRC government agencies, including MOFCOM, would deem that the M&A Rules required us or our entities in China
to obtain approval from MOFCOM or other PRC regulatory agencies in connection with JRSIS’s control of Jiarun.
If the CSRC, MOFCOM, or another PRC regulatory
agency subsequently determines that CSRC, MOFCOM or other approval was required for the share exchange transaction and/ or the
VIE arrangements between JRSIS and Jiarun, or if prior CSRC approval for this offering is required and not obtained, we may face
severe regulatory actions or other sanctions from MOFCOM, the CSRC or other PRC regulatory agencies. In such event, these regulatory
agencies may impose fines or other penalties on our operations in the PRC, limit our operating privileges in the PRC, delay or
restrict the repatriation of the proceeds from this offering into the PRC, restrict or prohibit payment or remittance of dividends
to us or take other actions that could have a material adverse effect on our business, financial condition, results of operations,
reputation and prospects, as well as the trading price of our common stock. The CSRC or other PRC regulatory agencies may also
take actions requiring us, or making it advisable for us, to delay or cancel this offering, to restructure our current corporate
structure, or to seek regulatory approvals that may be difficult or costly to obtain.
The M&A Rules, along with certain foreign
exchange regulations discussed below, will be interpreted or implemented by the relevant government authorities in connection with
our future offshore financings or acquisitions, and we cannot predict how they will affect our acquisition strategy. For example,
our operating companies' ability to remit dividends to us, or to engage in foreign-currency-denominated borrowings, may be conditioned
upon compliance with the SAFE registration requirements by such Chinese domestic residents, over whom we may have no control.
SAFE regulations relating to offshore
investment activities by PRC residents may increase our administrative burdens and restrict our overseas and cross-border investment
activity. If our shareholders and beneficial owners who are PRC residents fail to make any required applications, registrations
and filings under such regulations, we may be unable to distribute profits and may become subject to liability under PRC laws.
SAFE has promulgated several regulations, including
Notice on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents to Engage in Financing and Inbound Investment
via Oversea Special Purpose Vehicles, or "Circular No. 75," issued on October 21, 2005 and effective as of November 1,
2005 and certain implementation rules issued in recent years, requiring registrations with, and approvals from, PRC government
authorities in connection with direct or indirect offshore investment activities by PRC residents and PRC corporate entities. These
regulations apply to our shareholders and beneficial owners who are PRC residents, and may affect any offshore acquisitions that
we make in the future.
SAFE Circular No. 75 requires PRC residents,
including both PRC legal person residents and/or natural person residents to register with the local SAFE branch before establishing
or controlling any company outside of China for the purpose of equity financing with assets or equities of PRC companies, referred
to in the notice as an "offshore special purpose company." In addition, any PRC resident who is a direct or indirect
shareholder of an offshore company is required to update his registration with the relevant SAFE branches, with respect to that
offshore company, in connection with any material change involving an increase or decrease of capital, transfer or swap of shares,
merger, division, equity or debt investment or creation of any security interest.
Moreover, the PRC subsidiaries of that offshore
company are required to coordinate and supervise the filing of SAFE registrations by the offshore company's shareholders who are
PRC residents in a timely manner. If a PRC shareholder with a direct or indirect stake in an offshore parent company fails to make
the required SAFE registration, the PRC subsidiaries of such offshore parent company may be prohibited from making distributions
of profit to the offshore parent and from paying the offshore parent proceeds from any reduction in capital, share transfer or
liquidation in respect of the PRC subsidiaries, and the offshore parent company may also be prohibited from injecting additional
capital into its PRC subsidiaries. Furthermore, failure to comply with the various SAFE registration requirements described above
may result in liability for the PRC shareholders and the PRC subsidiaries under PRC law for foreign exchange registration evasion.
Although we have requested our PRC shareholders
to complete the SAFE Circular No. 75 registration, we cannot be certain that all of our PRC resident beneficial owners will comply
with the SAFE regulations. The failure or inability of our PRC shareholders to receive any required approvals or make any required
registrations may subject us to fines and legal sanctions, restrict our overseas or cross-border investment activities, prevent
us from transferring the net proceeds of this offering or making other capital injection into our PRC subsidiaries, limit our PRC
subsidiaries' ability to make distributions or pay dividends or affect our ownership structure, as a result of which our acquisition
strategy and business operations and our ability to distribute profits to you could be materially and adversely affected.
Under Operating Rules on the Foreign Exchange
Administration of the Involvement of Domestic Individuals in the Employee Stock Ownership Plans and Share Option Schemes of Overseas
Listed Companies, issued and effective as of March 28, 2007 by the State Administration of Foreign Exchange, or "SAFE"
("Circular No. 78"), the employee stock option plan or share incentive plan should be registered with the SAFE or its
local branches and complete certain other procedures related to the share option or other share incentive plan through the PRC
subsidiary of such overseas listed company or any other qualified PRC agent before such grants are made. We believe that all of
our PRC employees who are granted share options are subject to SAFE No. 78. In addition, PRC residents who are granted shares or
share options by an overseas listed company according to its employee share option or share incentive plan are required to obtain
approval from the SAFE or its local branches. We intend to grant our PRC employees stock options pursuant to an employee stock
option plan. We will request our PRC management, personnel, directors and employees who are to be granted stock options to register
them with local SAFE pursuant to Circular No.78. However, we cannot assure you that each of these individuals will successfully
comply with all the required procedures above. If we or our PRC security holders fail to comply with these regulations, we or our
PRC security holders may be subject to fines and legal sanctions. Further, failure to comply with the various SAFE registration
requirements described above could result in liability under PRC law for foreign exchange evasion and we may become subject to
a more stringent review and approval process with respect to our foreign exchange activities.
Risks Related to Doing Business in China
We depend upon the acquisition and maintenance of licenses
to conduct our business in the PRC.
In order to conduct business, especially in
chemical production activities in the PRC, we are required to maintain various licenses from the appropriate government authorities,
including general business licenses and licenses and/or permits specific to our pharmaceutical product retail and distribution
operations. We are required to maintain valid safety service licenses and other relevant licenses and permits to conduct our activities.
The applicable licenses are subject to periodic renewal. An application for renewal needs to be submitted at least 30 days before
the expiration date and the extension will be approved if the applicant satisfies all applicable requirements and pays appropriate
resource fee. The PRC government may amend relevant laws and discontinue approval of renewal of pharmaceutical related licenses.
Further, fees for such licenses may increase in the future. Our failure to obtain or maintain these licenses and any change of
the relevant PRC laws to our disadvantage will have a material adverse impact on our ability to conduct our business and on our
financial condition. No assurance can be given regarding the timing or magnitude of these types of government actions or that the
same will not have a negative impact on our operations.
Changes in current policies of the PRC
government could have a significant impact upon the business we conduct in the PRC and the profitability of our operations
.
Current policies adopted by the PRC government
indicate that it seeks to encourage a market oriented economy. We believe that the PRC government will continue to develop policies
that strengthen its economic and trading relationships with foreign countries and as a consequence, business development in the
PRC will follow current market forces. While we believe that this trend will continue, we cannot assure you that such beneficial
policies will not change in the future. A change in the current policies of the PRC government could result in confiscatory taxation,
restrictions on currency conversion, or the expropriation or nationalization of private enterprises, all of which would have a
negative impact on our current corporate structure and our operations. The PRC laws and regulations governing our current business
operations are sometimes vague and uncertain. Any changes in such PRC laws and regulations may have a material and adverse effect
on our business.
There are substantial uncertainties regarding
the interpretation and application of PRC laws and regulations, including, but not limited to, those laws and regulations governing
our business and those relating to the enforcement and operation of our contractual arrangements. At this time, we believe that
the relevant PRC laws and regulations validate our current contractual arrangements and that our corporate structure is in keeping
with such laws. However, no assurance can be given that PRC court rulings to be decided in the future will be consistent with our
current interpretations. Further, new laws or regulations may be enacted which could have a negative impact on foreign investors.
We cannot predict what effect the interpretation of existing or new PRC laws or regulations may have on our business and no assurance
can be given that our operations will not be affected by such laws and/or regulations.
The PRC government exerts substantial influence over the manner
in which companies in China must conduct their business activities.
The PRC only recently has permitted greater
provincial and local economic autonomy and private economic activities. The government of the PRC has exercised and continues to
exercise substantial control over virtually every sector of the Chinese economy through regulation and state ownership. Government
actions in the future, including any decision not to continue to support recent economic reforms and to return to a more centrally
planned economy or regional or local variations in the implementation of economic policies, could have a significant effect on
economic conditions in the PRC or particular regions thereof. If this were to occur, we may be required to divest the interests
we then control in Chinese properties. Any such developments could have a material adverse effect on our business, operations,
financial condition and prospects.
Future inflation in China may inhibit
economic activity and adversely affect our operations.
The Chinese economy has experienced periods
of rapid expansion in recent years which has led to high rates of inflation and deflation. This has caused the PRC government to,
from time to time, enact various corrective measures designed to restrict the availability of credit or regulate growth and contain
inflation. While inflation has subsided since 1995, high inflation may in the future cause the PRC government to once again impose
controls on credit and/or prices, or to take other action, which could inhibit economic activity in China. Any action on the part
of the PRC government that seeks to control credit and/or prices may adversely affect our business operations.
A slowdown or other adverse developments
in the PRC economy may materially and adversely affect our customers, demand for our products and our business.
We are a holding company and of our operations
are entirely conducted in the PRC. In addition, all of our revenues are currently generated from sales in the PRC. Although the
PRC economy has grown at a remarkable pace in recent years, we cannot assure you that such growth will continue. A slowdown in
overall economic growth, an economic downturn or recession or other adverse economic developments in the PRC may materially reduce
the demand for our products and have a materially adverse effect on our business.
We may be restricted from freely converting the Renminbi to
other currencies in a timely manner.
At the present time, the RMB is not a freely
convertible currency. We receive all of our revenue in RMB, which may need to be converted to other currencies, primarily U.S.
dollars, in order to be remitted outside of the PRC. Effective July 1, 1996, foreign currency “current account” transactions
by foreign investment enterprises are no longer subject to the approval of State Administration of Foreign Exchange (“SAFE,”
formerly, “State Administration of Exchange Control”), but need only a ministerial review, according to the Administration
of the Settlement, Sale and Payment of Foreign Exchange Provisions promulgated in 1996 (the “FX regulations”). “Current
account” items include international commercial transactions, which occur on a regular basis, such as those relating to trade
and provision of services. Distributions to joint venture parties also are considered “current account transactions.”
Other non-current account items, known as “capital account” items, remain subject to SAFE approval. Under current regulations,
we can obtain foreign currency in exchange for RMB from swap centers authorized by the government. While we do not anticipate problems
in obtaining foreign currency to satisfy our requirements; however, no assurance can be given that foreign currency shortages or
changes in currency exchange laws and regulations by the PRC government will not restrict us from freely converting RMB in a timely
manner.
Governmental control of currency conversion
may affect the value of your investment.
The PRC government imposes controls on the
convertibility of Renminbi into foreign currencies and, in certain cases, the remittance of foreign currency out of the PRC. We
receive all of our revenues in Renminbi, which is currently not a freely convertible currency. Shortages in the availability of
foreign currency may restrict our ability to remit sufficient foreign currency to pay dividends, or otherwise satisfy foreign currency
denominated obligations. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions,
interest payments and expenditures from the transaction, can be made in foreign currencies without prior approval from the PRC
State Administration of Foreign Exchange by complying with certain procedural requirements. However, approval from appropriate
governmental authorities is required where Renminbi is to be converted into foreign currency and remitted out of the PRC to pay
capital expenses such as the repayment of bank loans denominated in foreign currencies.
Further, the PRC government may also restrict
access to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining
sufficient foreign currency to satisfy our currency demands, we may not be able to pay certain of our expenses as they come due.
Fluctuations in the exchange rate could
have an adverse effect upon our business and reported financial results.
We conduct our business in Renminbi (“RMB”),
thus our functional currency is the RMB, while our reporting currency is the U.S. dollar. The value of the RMB against the U.S.
dollar and other currencies may fluctuate and is affected by, among other things, the political situation as well as economic policies
and conditions. On July 21, 2005, the PRC government changed its decade old policy of pegging its currency to the U.S. currency.
Under that policy, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies.
This change in policy has resulted in an approximate 21% appreciation of the RMB against the U.S. dollar between 2005 and 2008.
However, the PRC government decided to repeg the RMB to U.S. dollars in response to the financial crisis in 2008. On June 19, 2010,
China ended the pegging of the RMB to the U.S. dollar, allowing for a greater flexibility of its exchange rate. There remains significant
international pressure on the significant appreciation of the RMB against the U.S. dollar. To the extent any of our future revenues
are denominated in currencies other than the United States dollar, we would be subject to increased risks relating to foreign currency
exchange rate fluctuations which could have a material adverse effect on our financial condition and operating results since operating
results are reported in United States dollars and significant changes in the exchange rate could materially impact our reported
earnings.
Changes in PRC State Administration of
Foreign Exchange (“SAFE”) Regulations regarding offshore financing activities by PRC residents may increase the administrative
burden we face and create regulatory uncertainties that could adversely affect the implementation of our acquisition strategy.
In 2005, SAFE promulgated regulations which
require registrations with, and approval from, SAFE on direct or indirect offshore investment activities by PRC legal person resident
and/or natural person resident. The SAFE regulations require that if an offshore company formed by or controlled by PRC legal person
resident and/or natural person resident, whether directly or indirectly, intends to acquire a PRC company, such acquisition shall
be subject to strict examination and registration with SAFE. Without such registration, the PRC entity cannot remit any of its
profits out of the PRC, whether as dividends or otherwise. As such, the failure by our shareholders who are PRC residents to make
any required applications, filings or registrations pursuant to such SAFE regulations may prevent us from being able to distribute
profits and could expose us, as well as our PRC resident shareholders to liability under PRC law.
Because our principal assets are located
outside of the United States and most of our directors and officers reside outside of the United States, it may be difficult for
an investor to enforce any right founded on U.S. Federal Securities Laws against us and/or our officers and directors, or to enforce
a judgment rendered by a United States court against us or our officers and directors.
Our operation and principle assets are located
in the PRC, and our officers and directors are non-residents of the United States. Therefore, it may be difficult to effect service
of process on such persons in the United States, and it may be difficult to enforce any judgments rendered against us or our officers
and/or directors. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals
in China in the event that you believe that your rights have been infringed under the securities laws or otherwise. Even if you
are successful in bringing an action of this kind, the laws of the PRC may render you unable to enforce a judgment against our
assets or the assets of our directors and officers. As a result of all of the above, our shareholders may have more difficulty
in protecting their interests through actions against our management, directors or major shareholders compared to shareholders
of a corporation doing business entirely within the United States.
Regulatory Risks
State and Local Regulation
The Company may be subject to the separate
regulations pertaining to commercial private lenders, specific property types or specific types of borrowers in each particular
state, county, municipality or country. The Company may fail to comply with all of such regulations, or may incur significant costs
in complying with such regulations.
Usury Laws
Although the Company intends for the Company’s debt to be
fully compliant with law, the terms of such debts may be determined by a court to be usurious.
Risks Relating to Our Common Stock
We are an emerging growth company and, as a result of the
reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive
to investors.
We are an emerging growth company, as defined
in the JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting requirements applicable to
other public companies, but not to emerging growth companies, including, but not limited to, a requirement to present only two
years of audited financial statements, an exemption from the auditor attestation requirement of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure about executive compensation arrangements pursuant to the rules applicable to smaller reporting companies
and no requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements, although some
of these exemptions are available to us as a smaller reporting company (i.e. a company with less than $75 million of its voting
equity held by affiliates). We have elected to adopt these reduced disclosure requirements. We cannot predict
if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If
some investors find our common stock less attractive as a result of our choices, there may be a less active trading market for
our common stock and our stock price may be more volatile.
Pursuant to Section 107(b) of the JOBS Act,
we have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2)
of The JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective
dates for public and private companies until those standards apply to private companies. As a result, our financial statements
may not be comparable to companies that comply with public company effective dates. The decision to opt out is irrevocable.
Because the worldwide market value of our common
stock held by non-affiliates, or public float, is below $75 million, we are also a “smaller reporting company” as defined
under the Exchange Act. Some of the foregoing reduced disclosure and other requirements are also available to us because we are
a smaller reporting company and may continue to be available to us even after we are no longer an emerging growth company under
the JOBS Act but remain a smaller reporting company under the Exchange Act. As a smaller reporting company we are not required
to:
|
·
|
have
an auditor report on our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; and
|
|
·
|
present
more than two years of audited financial statements in our registration statements and annual reports on Form 10-K and present
any selected financial data in such registration statements and annual reports filings made by the Company on the EDGAR Company
Search page of the Securities and Exchange Commission's Web site, the address for which is www.sec.gov. The public may read and
copy any materials the Company files with the SEC at the SEC's Public.
|
Because we are subject to “penny stock” rules,
the level of trading activity in our stock may be reduced.
Broker-dealer practices in connection with
transactions in “penny stocks” are regulated by penny stock rules adopted by the Securities and Exchange Commission.
Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on some national
securities exchanges). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt
from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature
and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations
for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and, if the broker-dealer is
the sole market maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market,
and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition,
broker-dealers who sell these securities to persons other than established customers and “accredited investors” must
make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s
written agreement to the transaction. Consequently, these requirements may have the effect of reducing the level of trading activity,
if any, in the secondary market for a security subject to the penny stock rules. If a trading market does develop for our common
stock, these regulations will likely be applicable, and investors in our common stock may find it difficult to sell their shares.
FINRA sales practice requirements may
limit a stockholder’s ability to buy and sell our stock.
FINRA has adopted rules that require that in
recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable
for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers
must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives
and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low
priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers
to recommend that their customers buy our common stock, which may have the effect of reducing the level of trading activity in
our common stock. As a result, fewer broker-dealers may be willing to make a market in our common stock, reducing a stockholder’s
ability to resell shares of our common stock.
Our insiders beneficially own a significant portion of our
stock, and accordingly, may have control over stockholder matters, the Company’s business and management.
The percentage ownership information shown
in the table below is calculated based on 13,915,000 shares of our common stock issued and outstanding as of June 30, 2017. We
do not have any outstanding options, warrants or other securities exercisable for or convertible into shares of our common stock.
|
|
|
|
Amount and
Nature
|
|
|
|
|
Title of
|
|
|
|
of Beneficial
|
|
|
|
|
Class
|
|
Name of Beneficial Owner
|
|
Ownership
|
|
|
Percentage
|
|
Common Stock
|
|
Junsheng Zhang
|
|
|
11,160,000
|
|
|
|
80.2
|
%
|
|
|
President, Chairman of the board.
|
|
|
Direct
|
|
|
|
|
|
Common Stock
|
|
Sujuan Peng
|
|
|
252,000
|
|
|
|
1.81
|
%
|
|
|
|
|
|
Direct
|
|
|
|
|
|
Common Stock
|
|
Yanhua Xing
|
|
|
588,000
|
|
|
|
4.23
|
%
|
|
|
|
|
|
Direct
|
|
|
|
|
|
|
|
All Officers and Directors as a Group
|
|
|
12,000,000
|
|
|
|
86.24
|
%
|
As a result, our executive officers, directors and affiliated persons
will have significant influence to:
|
·
|
Elect or defeat the election of our directors;
|
|
·
|
Amend or prevent amendment of our articles of incorporation
or bylaws;
|
|
·
|
Effect or prevent a merger, sale of assets or other corporate
transaction; and
|
|
·
|
Affect the outcome of any other matter submitted to the
stockholders for vote.
|
Moreover, because of the significant ownership position held by
our insiders, new investors will not be able to effect a change in the Company’s business or management, and therefore, shareholders
would be subject to decisions made by management and the majority shareholders.
In addition, sales of significant amounts of shares held by our
directors and executive officers, or the prospect of these sales, could adversely affect the market price of our common stock.
Management’s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain
control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price.
The sale of securities by us in any equity or debt financing
could result in dilution to our existing stockholders and have a material adverse effect on our earnings.
We are authorized to issue up to 100,000,000
shares of common stock, of which 13,915,000 shares are issued and outstanding. Our Board of Directors has the authority to cause
us to issue additional shares of common stock, and to determine the rights, preferences and privilege of such shares, without consent
of any of our stockholders. Any sale of common stock by us in a future private placement offering could result in dilution to the
existing stockholders as a direct result of our issuance of additional shares of our capital stock. In addition, our business strategy
may include expansion through internal growth by acquiring complementary businesses, acquiring or licensing additional brands,
or establishing strategic relationships with targeted customers and suppliers. In order to do so, or to finance the cost of our
other activities, we may issue additional equity securities that could dilute our stockholders’ stock ownership. We may also
assume additional debt and incur impairment losses related to goodwill and other tangible assets, and this could negatively impact
our earnings and results of operations.
If securities or industry analysts do
not publish research or reports about our business, or if they downgrade their recommendations regarding our common stock, our
stock price and trading volume could decline.
The trading market for our common stock may
be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the
analysts who cover us downgrade our common stock, our common stock price would likely decline. If analysts cease coverage of our
company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause
our common stock price or trading volume to decline.
If we continue to fail to maintain an
effective system of internal controls, we might not be able to report our financial results accurately or prevent fraud; in that
case, our stockholders could lose confidence in our financial reporting, which could negatively impact the price of our stock.
Effective internal controls are necessary for
us to provide reliable financial reports and prevent fraud. In addition, Section 404 of the Sarbanes-Oxley Act of 2002, or
the Sarbanes-Oxley Act, requires us to evaluate and report on our internal control over financial reporting for all our current
operations. The process of implementing our internal controls and complying with Section 404 will be expensive and time -
consuming, and will require significant attention of management. We cannot be certain that these measures will ensure that we implement
and maintain adequate controls over our financial processes and reporting in the future. Even if we conclude, and our independent
registered public accounting firm concurs, that our internal control over financial reporting provides reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles, because of its inherent limitations, internal control over financial reporting may not prevent
or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their
implementation, could harm our operating results or cause us to fail to meet our reporting obligations. If we or our independent
registered public accounting firm discover a material weakness or a significant deficiency in our internal control, the disclosure
of that fact, even if quickly remedied, could reduce the market’s confidence in our financial statements and harm our stock
price. In addition, a delay in compliance with Section 404 could subject us to a variety of administrative sanctions, including
ineligibility for short form resale registration, action by the Securities and Exchange Commission, and the inability of registered
broker-dealers to make a market in our common stock, which could further reduce our stock price and harm our business.
Because we do not intend to pay any dividends
on our common stock, holders of our common stock must rely on stock appreciation for any return on their investment.
There are no restrictions in our Articles of
Incorporation or Bylaws that prevent us from declaring dividends. The Florida Revised Statutes, however, do prohibit us from declaring
dividends where, after giving effect to the distribution of the dividend we would not be able to pay our debts as they become due
in the usual course of business; or our total assets would be less than the sum of our total liabilities plus the amount that would
be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution. We paid
dividends on our common stock in 2013, we do not anticipate paying any such dividends for the foreseeable future. Accordingly,
holders of our common stock will have to rely on capital appreciation, if any, to earn a return on their investment in our common
stock.
The requirements of being a public company
may strain our resources, divert management’s attention and affect our ability to attract and retain qualified members for
our Board of Directors.
As a public company, we will be subject to
the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Sarbanes-Oxley
Act. The requirements of these rules and regulations increase our legal, accounting and financial compliance costs, may make some
activities more difficult, time-consuming and costly and may also place undue strain on our personnel, systems and resources. In
order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting,
we will need to expend significant resources and provide significant management oversight. We have a substantial effort ahead of
us to implement appropriate processes, document our system of internal control over relevant processes, assess their design, remediate
any deficiencies identified and test their operation. As a result, management’s attention may be diverted from other business
concerns, which could harm our business, operating results and financial condition. These efforts will also involve substantial
accounting-related costs.
As a result of these and other factors, our
operating results may not meet the expectations of investors or public market analysts who choose to follow our company. Our failure
to meet market expectations would likely result in decreases in the trading price of our common stock.
CAUTIONARY STATEMENT
REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking
statements and information relating to our business that are based on our beliefs as well as assumptions made by us or based upon
information currently available to us. These statements reflect our current views and assumptions with respect to future events
and are subject to risks and uncertainties. Forward-looking statements are often identified by words like: “believe,”
“expect,” “estimate,” “anticipate,” “intend,” “project” and similar
expressions or words which, by their nature, refer to future events. In some cases, you can also identify forward-looking statements
by terminology such as “may,” “will,” “should,” “plans,” “predicts,”
“potential” or “continue” or the negative of these terms or other comparable terminology. These statements
are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled
Risk Factors beginning on page 6, that may cause our or our industry’s actual results, levels of activity, performance or
achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. In addition, you are directed to factors discussed in the Management’s Discussion and
Analysis of Financial Condition and Results of Operation section beginning on page 16, and the section entitled “Overview”
beginning on page 16, and as well as those discussed elsewhere in this prospectus. Other factors include, among others: general
economic and business conditions; industry capacity; industry trends; competition; changes in business strategy or development
plans; project performance; availability, terms, and deployment of capital; and availability of qualified personnel.
These forward-looking statements speak only
as of the date of this prospectus. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, levels of activity, or achievements. Except as required by applicable law, including the securities
laws of the United States, we expressly disclaim any obligation or undertaking to disseminate any update or revisions of any of
the forward-looking statements to reflect any change in our expectations with regard thereto or to conform these statements to
actual results.
TAX CONSIDERATIONS
We are not providing any tax advice as to the
acquisition, holding or disposition of the securities offered herein. In making an investment decision, investors are strongly
encouraged to consult their own tax advisor to determine the U.S. federal, state and any applicable foreign tax consequences relating
to their investment in our securities.
USE OF PROCEEDS
We will not receive any proceeds from the sales, if any, of the
common stock covered by this prospectus. All net proceeds from the sale of the common stock covered by this prospectus will go
to the selling stockholder. See “Selling Stockholder” and “Plan of Distribution” described below.
DETERMINATION OF THE OFFERING PRICE
Our shares of common stock are currently listed,
it is trading on the OTCQB. On October 23, 2015, FINRA cleared the shares of JRSIS Health Care Corporation’s common stock
to commence trading on the OTCQB under the symbol “JRSS,” and our shares were approved for DTC Eligibility on December
21, 2015. The offering price of the securities offered by Selling Stockholders will be determined by the prevailing market price
for the common shares at the time of sale or negotiated transactions.
Holders of Securities
As of June 30, 2017, we had 101 holders of
our common stock, and we have 13,915,000 shares of common stock, par value $0.001 outstanding. All of our shareholders are non
U.S. citizens and all reside outside the United States. We have 1,915,000 shares eligible for sale pursuant to Regulation S. In
general, under Regulation S as currently in effect, a person who is not one of our officers, directors, or principal shareholders,
and who has owned their shares for at least one year, may sell their shares without limitation in the public market.
Dividends
We have not declared or paid any cash dividends on our common stock
since our inception, and our board of directors currently intends to retain all earnings for use in the business for the foreseeable
future. Any future payment of dividends will depend upon our results of operations, financial condition, cash requirements and
other factors deemed relevant by our board of directors. There are currently no restrictions that limit our ability to declare
cash dividends on its common stock and we do not believe that there are any that are likely to do so in the future.
MANAGEMENT’S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
The following discussion of our financial
condition and results of operation should be read in conjunction with the financial statements and related notes that appear elsewhere
in this prospectus. This discussion contains forward-looking statements and information relating to our business that reflect our
current views and assumptions with respect to future events and are subject to risks and uncertainties, including the risks in
the section entitled Risk Factors beginning on page 6, that may cause our or our industry’s actual results, levels of activity,
performance or achievements to be materially different from any future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements.
These forward-looking statements speak only
as of the date of this prospectus. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, levels of activity, or achievements. Except as required by applicable law, including the securities
laws of the United States, we expressly disclaim any obligation or undertaking to disseminate any update or revisions of any of
the forward-looking statements to reflect any change in our expectations with regard thereto or to conform these statements to
actual results.
Our financial statements are stated in United
States Dollars and are prepared in accordance with accounting principles generally accepted in the United States.
Overview
Harbin Jiarun Hospital Company Limited (“Jiarun Hospital”)
was established in Harbin in the Province of Heilongjiang of the People’s Republic of China (“PRC”) by the owner
Junsheng Zhang on February 17, 2006.
Jiarun is a private hospital serving patients on a municipal and
county level and providing both Western and Chinese medical practices to the residents of Harbin. Jiarun specializes in the areas
of Pediatrics, Dermatology, ENT, Traditional Chinese Medicine (TCM), Ophthalmology, Internal Medicine Dentistry, General Surgery,
Rehabilitation Science, Gynecology, General Medical Services, etc.
On November 20, 2013, Junsheng Zhang, the officer of Jiarun Hospital
established JRSIS HEALTH CARE CORPORATION, a Florida corporation (“JHCC” or the “Company”). On February
25, 2013, the officer of Jiarun Hospital established JRSIS HEALTH CARE LIMITED ("JHCL"), a wholly owned subsidiary of
the Company, and On September 17, 2012, the officer of Jiarun Hospital established Runteng Medical Group Co., Ltd (“Runteng”),
a wholly owned subsidiary of JHCL. Runteng, a Hong Kong registered Investment Company, holds a seventy percent (70%) ownership
interest in Harbin Jiarun Hospital Company Ltd, a Heilongjiang registered company.
On December 20, 2013, the Company acquired One Hundred Percent (100%)
of the issued and outstanding capital stock of JRSIS Health Care Limited, a privately held Limited Liability Company registered
in the British Virgin Islands (“JHCL”) for Twelve Million (12,000,000) shares of our common stock. JHCL, through its
wholly owned subsidiary, Runteng Medical Group Co., Ltd (“Runteng”), holds majority ownership in Harbin Jiarun Hospital
Co., Ltd, a company duly incorporated, organized and validly existing under the laws of China (“Jiarun”). As the parent
company, JHCC rely on Jiarun Hospital to conduct One Hundred Percent (100%) of our businesses and operations.
We have two sources of patient revenues: in-patient
service revenues and out-patient service revenues. In addition to provide services to our patients, we also sell pharmaceutical
medicines to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service
revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers,
under which the hospital is paid based upon local government established charges. Revenue from the sale of medicine is recognized
when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine,
ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all
of which generally occur when the patient receives the medicine. Patient service revenue is recognized when it is both earned and
realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the
patient and collection of the revenue is reasonably assured.
Plan of Operation
Over the next twelve months, we will concentrate
on the following two areas to grow our operations:
|
●
|
Capital
and Funding – Seek to obtain capital from all available sources to complete our hospital expansion and acquisition targets.
|
|
●
|
Advertising and Marketing – Work with several marketing
companies to develop brand identity, marketing materials, and update our web site. Utilize all available marketing venues and
public relations opportunities to promote the Company and its medicine and services. In April, 2014, we also bought a mobile clinic
to provide free health examinations in the hospital area. Management believes this free service will bring us much higher brand
reputation and potential customers locally.
|
Critical Accounting Policies and Management
Estimates
Our discussion and analysis of our financial
condition and results of operations relates to our consolidated financial statements, which have been prepared in accordance with
the United States generally accepted accounting principles ("U.S. GAAP"). The consolidated financial statements include
the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated
in consolidation.
Principles of Consolidation
The consolidated financial statements include
the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. Non-controlling interest
is reported in the consolidated financial position within equity, separately from the Company’s equity and that net income
or loss and comprehensive income or loss are attributable to the Company’s and the non-controlling interest.
Use of Estimates
The preparation of audited consolidated financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts
of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at
the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates
and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives
of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable
but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
Revenue Recognition
The Company recognizes revenue when the amount of revenue can be
reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of
the Company's activities as described below.
Medicine sales
Revenue from the sale of medicine is recognized when it is both
earned and realized. The Company's policy is to recognize the sale of medicine when the title of the medicine, ownership and risk
of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally
occur when the patient receives the medicine.
Given the nature of this revenue source of
the Company's business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of
medicine do not contain estimates that materially affect results of operations nor any policy for return of products.
Patient services
In accordance with the medical licenses of Jiarun, the approved
medical patient service scope of the Company includes medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia,
clinic laboratory, medical imaging, and traditional Chinese medicine, etc.
Patient service revenue is recognized when it is both earned and
realized. The Company's policy is to recognize patient service revenue when the medical service has been provided to the patient
and collection of the revenue is reasonably assured.
The Company provides services to both patients covered by social
insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless
of the coverage by social insurance.
Patients who are not covered by social insurance are liable for
the total cost of medical treatment.
|
·
|
For
out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects
payment when the patient checks out from the hospital, which is the same day the services are provided
|
|
·
|
For
in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients'
symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient
and records the payment as deposits received.
|
During the in-patient services period, the Company recognizes revenue
when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions
based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the
Company records revenue and accounts receivable when the patient services are provided.
When patients check out from the hospital, the Company calculates
and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where
the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in
full at checkout.
Patients covered by social insurance will receive a portion or full
medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.
Settlement process
The Company is a registered medical service vendor under the
state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance
funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”.
The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social
insurance agencies.
|
·
|
The
Company records patients’ information in the social insurance system at check in. The system determines the covered portion
and amounts based on the information input to the system.
|
|
·
|
At
the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from
the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have
made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.
|
|
·
|
The
Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their
review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance
agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following
the approval.
|
Income Taxes and Uncertain Tax Positions
The Company adopts FASB ASC Topic 740, "Income Taxes,"
which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have
been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences
in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period
end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be
realized.
In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for
Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet
a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions
that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting
period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold
should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.
The application of tax laws and regulations is subject to legal
and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of
changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability
may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially
reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
As a result of the implementation of FIN 48 (ASC 740-10), the company
made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC
740-10). The Company recognized no material adjustments to liabilities or shareholder's equity as a result of the implementation.
The adoption of FIN 48 did not have a material impact on the Company's unaudited consolidated financial statements.
Enterprise income tax is defined under the Provisional Regulations
of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their
taxable income.
Jiarun's medical services have been exempt from enterprise income
tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with the law of medical and
health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3)
medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall
be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievement of the hospital,
it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $919 and
$864 for the three months ended March 31, 2017 and 2016, respectively to support the local tax bureau's economical obligations.
Accounts Receivable
Accounts receivable are recorded at net realizable value consisting
of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company's
best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the
allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances
are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered
remote.
Property and Equipment
Property and equipment are stated at cost. Expenditures for maintenance
and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded
on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset's original
cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.
Buildings and improvement
|
|
10-40 years
|
Medical equipment
|
|
5-15 years
|
Transportation instrument
|
|
5-10 years
|
Office equipment
|
|
5-10 years
|
Electronic equipment
|
|
5-10 years
|
Software
|
|
5-10 years
|
Functional Currency and Foreign Currency Translations
JHCC and JHCL’s functional currency is the United States dollar
(“US$”). Runteng’s functional currency is the Hong Kong dollar (“HK$”). The functional currency of
Jiarun is the Renminbi (“RMB”).
The Company’s reporting currency is US$.
Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and
expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical
rates. Translation adjustments are reported in other comprehensive income.
Results of Operations for the Years Ended
December 31, 2016 and 2015
The following table shows key components of
the results of operations during the years ended December 31, 2016 and 2015:
|
|
For the Year Ended
December 31,
|
|
|
Change
|
|
|
|
2016
|
|
|
2015
|
|
|
$
|
|
|
%
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Medicine
|
|
$
|
7,998,195
|
|
|
$
|
5,503,971
|
|
|
$
|
2,494,224
|
|
|
|
45
|
%
|
Patient services
|
|
|
10,120,550
|
|
|
|
6,368,432
|
|
|
|
3,752,118
|
|
|
|
59
|
%
|
Total revenue
|
|
|
18,118,745
|
|
|
|
11,872,403
|
|
|
|
6,246,342
|
|
|
|
53
|
%
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of medicine sold
|
|
|
4,882,316
|
|
|
|
3,331,264
|
|
|
|
1,551,052
|
|
|
|
47
|
%
|
Medical consumables
|
|
|
1,747,917
|
|
|
|
839,702
|
|
|
|
908,215
|
|
|
|
108
|
%
|
Salaries and benefits
|
|
|
2,861,888
|
|
|
|
1,876,362
|
|
|
|
985,526
|
|
|
|
53
|
%
|
Office supplies
|
|
|
378,691
|
|
|
|
351,353
|
|
|
|
27,338
|
|
|
|
8
|
%
|
Vehicle expenses
|
|
|
56,605
|
|
|
|
36,013
|
|
|
|
20,592
|
|
|
|
57
|
%
|
Utilities expenses
|
|
|
443,054
|
|
|
|
491,209
|
|
|
|
(48,155
|
)
|
|
|
(10
|
%)
|
Advertising and promotion expenses
|
|
|
119,156
|
|
|
|
-
|
|
|
|
119,156
|
|
|
|
NA
|
|
Interest expense
|
|
|
1,384,826
|
|
|
|
1,244,185
|
|
|
|
140,641
|
|
|
|
11
|
%
|
Professional fee
|
|
|
140,059
|
|
|
|
200,904
|
|
|
|
(60,845
|
)
|
|
|
(30
|
%)
|
Depreciation
|
|
|
1,081,123
|
|
|
|
871,948
|
|
|
|
209,175
|
|
|
|
24
|
%
|
Total operating costs and expenses
|
|
|
13,095,635
|
|
|
|
9,242,940
|
|
|
|
3,852,695
|
|
|
|
42
|
%
|
Earnings from operations before other income and income taxes
|
|
|
5,023,110
|
|
|
|
2,629,463
|
|
|
|
2,393,647
|
|
|
|
91
|
%
|
Other income
|
|
|
934
|
|
|
|
9,321
|
|
|
|
(8,387
|
)
|
|
|
(90
|
%)
|
Earnings from operations before income taxes
|
|
|
5,024,044
|
|
|
|
2,638,784
|
|
|
|
2,385,260
|
|
|
|
90
|
%
|
Income tax
|
|
|
4,059
|
|
|
|
2,604
|
|
|
|
1,455
|
|
|
|
56
|
%
|
Net income
|
|
|
5,019,985
|
|
|
|
2,636,180
|
|
|
|
2,383,805
|
|
|
|
90
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
(744,676
|
)
|
|
|
(392,923
|
)
|
|
|
(351,753
|
)
|
|
|
90
|
%
|
Comprehensive income
|
|
$
|
4,275,309
|
|
|
$
|
2,243,257
|
|
|
$
|
2,032,052
|
|
|
|
91
|
%
|
Revenue
Operating revenue for the year ended December
31, 2016, which resulted primarily from medicine revenue and patient services revenue, was $18,118,745, an increase of 53% as compared
with the operating revenue of $11,872,403 for the year ended December 31, 2015. The increase was primarily a result of the number
of treated inpatients growing to 14,276 patients, 4,036 more than the 10,240 patients treated in the year ended December 31, 2015.
Costs and expenses
Total costs and expenses were $13,095,635 for
the year ended December 31, 2016, an increase of $3,852,695 or 42% as compared to $9,242,940 for the same period of 2015. This
increase was primarily due to significant increases cost of medicine supplies of approximately $1,551,052, and increase in medical
consumables of $908,215 and increase in Depreciation and amortization of 209,175 and salaries and benefits of 985,526.
Cost of medicine sold
Cost of medicine sold mainly consists of cost
of Western medicine, Chinese medicine and herbal medicine. Total cost of medicine sold was $4,882,316 for the year ended December
31, 2016, an increase of $1,551,052 or 47% as compared to $3,331,264 for the same period of 2015. This increase was primarily due
to significant increases in cost of Western medicine and Chinese medicine of $1,495,534. For the year ended December 31, 2016,
the cost of Western medicine and Chinese medicine were $4,764,468, as compared to $3,268,935 for the same period of 2015.
Medical consumables
Medical consumables mainly consist of materials
expenses, medical film expenses and test reagent. Total medical consumables were $1,747,917 for the year ended December 31, 2016,
an increase of $908,215 or 108% as compared to $839,702 for the same period of 2015. The increase was mainly a result of increase
in materials expenses of $546,193 and increase in consultation expenses of $106,733, and increase in test reagent expense of $119,847.
Salaries and benefits
Salaries and benefits mainly consist of salaries
expenses, and social insurance expenses. Total salaries and benefits were $2,861,888 for the year ended December 31, 2016, an increase
of $985,526 or 53% as compared to $1,876,362 for the same period of 2015. The increase was mainly a result of increase in salaries
expenses of $918,411 and increase in social insurance expenses of $67,187.
Depreciation and amortization
Total Depreciation and amortization was $1,081,123
for the year ended December 31, 2016, an increase of $209,175 or 24% as compared to $871,948 for the same period of 2015.The increase
was mainly a result of increase in depreciation of 206,987.
Income taxes
Enterprise income tax is defined under the
Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises
at a rate of 25% of their taxable income.
Jiarun's medical services have been exempt
from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with
the law of medical and health institutions mainly provides medical services, with the "PRC Business Tax Tentative Regulations"
Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services
shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievements of the hospital,
they could not have been reached without the support of local authorities, Jiarun hospital has voluntarily paid income tax voluntary
of $4,059 and $2,604 for the years ended December 31, 2016 and 2015, respectively to support the local tax bureau's economical
obligations.
Income from operations and net income
Income from Operations was $5,023,110 for the
year ended December 31, 2016, as compared with operating income of $2,629,463 for the year ended December 31, 2015. The Company’s
net income for the year ended December 31, 2016 was $5,019,985 representing an increase of $2,383,805 or 90%, over $2,636,180 for
the year ended December 31, 2015. The increase of income from operations and net income for the year ended December 31, 2016 were
primarily due to aforementioned changes in operating revenue and operating expenses.
Liquidity and Capital Resources
The accompanying financial statements have
been prepared for the Company to continue as a going concern which contemplates, among other things, the realization of assets
and satisfaction of liabilities in the ordinary course of business.
As of December 31, 2016, the Company had approximately
$890,662 of cash and cash equivalents.
We are presently able to meet our obligations
as they come due. As of December 31, 2016, we had non-controlling interest of $5,052,518 and shareholders’ equity of
$6,634,336.
We anticipate that our future liquidity requirements
will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources of funding
for such requirements are expected to be cash generated from operations and raising additional funds from the public offering and/or
debt financing. However, we can provide no assurances that we will be able to generate sufficient cash flow from operations and/or
obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.
Cash Flows and Capital Resources
We believe that we will generate cash flow
from our business, which, along with our available cash, will provide sufficient liquidity and financial flexibility.
Our cash flows are summarized below:
|
|
The Year Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Net cash provided by operating activities
|
|
|
4,986,466
|
|
|
|
2,531,639
|
|
Net cash used in investing activities
|
|
|
(3,610,797
|
)
|
|
|
(4,532,655
|
)
|
Net cash used in (provided by) financing activities
|
|
|
(776,198
|
)
|
|
|
1,335,318
|
|
Effect of exchange rate fluctuation on cash and cash equivalents
|
|
|
(60,962
|
)
|
|
|
(28,634
|
)
|
Net (decrease) increase in cash and cash equivalents
|
|
|
538,509
|
|
|
|
(694,332
|
)
|
Cash and cash equivalents, beginning of period
|
|
|
352,153
|
|
|
|
1,046,485
|
|
Cash and cash equivalents, ending of period
|
|
$
|
890,662
|
|
|
$
|
352,153
|
|
Net Cash Provided by Operating Activities
For the year ended December 31, 2016, we had
positive cash flow from operating activities of $4,986,466, an increase of $2,454,827 from the same period of 2015, during which
we had cash flow from operating activities of $2,531,639. The net income for the year ended December 31, 2016 increase by $2,383,805
as compared to the year ended December 31, 2015. The increase in net cash provided by operating activities was also the result
of several factors, mainly including:
|
·
|
An increase of due to related parties’ items totaling
$883,027, which was due to the decrease in payment to related parties.
|
|
·
|
An increase of due to accounts payable items totaling $352,514,
which was the increase in procurement of medicines and equipment.
|
Net Cash Used in Investing Activities
Net cash used in investing activities for the
year ended December 31, 2016 was $3,610,797, compared to net cash used in investing activities of $4,532,655 for the year ended
December 31, 2015. The cash used in investing activities for the year ended December 31, 2016, was mainly used for the purchase
of medical equipment.
Net Cash Provided by Financing Activities
Net cash used in financing activities for the
year ended December 31, 2016 was $776,198, as compared to net cash provided by financing activities of $1,335,318 for the year
ended December 31, 2015. The cash used in financing activities increased for the year ended December 31, 2016 was mainly due to
proceeds from finance lease decreased $2,350,085 and increased in payments on capital lease obligation $1,148,692.
Results of Operations for Three Months Ended
March 31, 2017 and 2016
The following table shows key components of
the results of operations during three months ended March 31, 2017 and 2016:
|
|
Three Months Ended
March 31,
|
|
|
Change
|
|
|
|
2017
|
|
|
2016
|
|
|
$
|
|
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medicine
|
|
$
|
2,528,075
|
|
|
$
|
1,925,675
|
|
|
$
|
602,400
|
|
|
|
31
|
%
|
Patient services
|
|
|
2,982,737
|
|
|
|
2,482,956
|
|
|
|
499,781
|
|
|
|
20
|
%
|
Total revenue
|
|
|
5,510,812
|
|
|
|
4,408,631
|
|
|
|
1,102,181
|
|
|
|
25
|
%
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of medicine sold
|
|
|
1,650,466
|
|
|
|
1,106,181
|
|
|
|
544,285
|
|
|
|
49
|
%
|
Medical consumables
|
|
|
558,302
|
|
|
|
389,760
|
|
|
|
168,542
|
|
|
|
43
|
%
|
Salaries and benefits
|
|
|
814,366
|
|
|
|
682,590
|
|
|
|
131,776
|
|
|
|
19
|
%
|
Office supplies
|
|
|
119,302
|
|
|
|
81,806
|
|
|
|
37,496
|
|
|
|
46
|
%
|
Vehicle expenses
|
|
|
21,480
|
|
|
|
9,571
|
|
|
|
11,909
|
|
|
|
124
|
%
|
Utilities expenses
|
|
|
147,887
|
|
|
|
146,107
|
|
|
|
1,780
|
|
|
|
1
|
%
|
Advertising and promotion expenses
|
|
|
614
|
|
|
|
43,921
|
|
|
|
(43,307
|
)
|
|
|
(99
|
%)
|
Interest expense
|
|
|
289,939
|
|
|
|
343,818
|
|
|
|
(53,879
|
)
|
|
|
(16
|
%)
|
Professional fee
|
|
|
13,762
|
|
|
|
4,423
|
|
|
|
9,339
|
|
|
|
211
|
%
|
Depreciation
|
|
|
303,001
|
|
|
|
240,285
|
|
|
|
62,716
|
|
|
|
26
|
%
|
Total operating costs and expenses
|
|
|
3,919,119
|
|
|
|
3,048,462
|
|
|
|
870,657
|
|
|
|
29
|
%
|
Earnings from operations before other income and income taxes
|
|
|
1,591,693
|
|
|
|
1,360,169
|
|
|
|
231,524
|
|
|
|
17
|
%
|
Other (expenses) income
|
|
|
(2,930
|
)
|
|
|
1,269
|
|
|
|
4,199
|
|
|
|
(331
|
%)
|
Earnings from operations before income taxes
|
|
|
1,588,763
|
|
|
|
1,361,438
|
|
|
|
227,325
|
|
|
|
17
|
%
|
Income tax
|
|
|
919
|
|
|
|
864
|
|
|
|
55
|
|
|
|
6
|
%
|
Net income
|
|
|
1,587,844
|
|
|
|
1,360,574
|
|
|
|
227,270
|
|
|
|
17
|
%
|
Less: net income attributable to non-controlling interests
|
|
|
476,353
|
|
|
|
420,273
|
|
|
|
56,080
|
|
|
|
13
|
%
|
Net income attributable to the Company
|
|
$
|
1,111,491
|
|
|
$
|
940,301
|
|
|
$
|
171,190
|
|
|
|
18
|
%
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment attributable to non-controlling interests
|
|
|
28,360
|
|
|
|
21,262
|
|
|
|
7,098
|
|
|
|
33
|
%
|
Foreign currency translation adjustment attributable to the Company
|
|
|
18,413
|
|
|
|
30,496
|
|
|
|
(12,083
|
)
|
|
|
(40
|
%)
|
Comprehensive income
|
|
$
|
1,634,617
|
|
|
$
|
1,412,332
|
|
|
$
|
222,285
|
|
|
|
16
|
%
|
Revenue
Operating revenue for the three months ended
March 31, 2017, which resulted primarily from medicine revenue and patient services revenue, was $5,510,812, an increase of 25%
as compared with the operating revenue of $4,408,631 for the three months ended March 31, 2016. The increase was primarily a result
of the number of treated inpatients growing to 4,398 patients, about 644 more than the 3,754 patients treated in three months ended
March 31, 2016.
Costs and Expenses
Total costs and expenses were $3,919,119 for
the three months ended March 31, 2017, an increase of $870,657 or 29% as compared to $3,048,462 for the same period of 2016. This
increase was primarily due to significant increase of cost of medicine sold of $544,285, office supplies of $37,496, medical consumables
of $168,542, salaries and benefits of $131,776 and depreciation of $62,716.
Cost of medicine sold
Cost of medicine sold mainly consists of cost
of Western medicine, Chinese medicine and herbal medicine. Total cost of medicine sold was $1,650,466 for the three months ended
March 31, 2017, an increase of $544,285 or 49% as compared to $1,106,181 for the same period of 2016.This increase was primarily
due to significant increases in sales of Western medicine and Chinese medicine. For the three months ended March 31, 2017, the
cost of Western medicine and Chinese medicine were $1,608,322, as compared to $1,075,215 for the same period of 2016.
Medical consumables
Medical consumables mainly consist of materials
expenses, medical film expenses and test reagent. Total medical consumables were $558,302 for the three months ended March 31,
2017, an increase of $168,542 or 43% as compared to $389,760 for the same period of 2016.The increase was mainly a result of increase
in materials expenses of $103,689.
Salaries and benefits
Salaries and benefits mainly consist of salary
expenses, and social insurance expenses. Total salaries and benefits were $814,366 for the three months ended March 31, 2017, an
increase of $131,776 or 19% as compared to $682,590 for the same period of 2016. The increase was mainly a result of increase in
salary expenses of $116,820 and increase in social insurance expenses of $14,969. The number of employees was 557, an increase
of 89 as compared to 468 for the same period of 2016.
Income Taxes
Enterprise income tax is defined under the
Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC. Income tax is payable by enterprises
at a rate of 25% of their taxable income.
Jiarun's medical services have been exempt
from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with
the law of medical and health institutions to mainly provide medical services, with the "PRC Business Tax Tentative Regulations"
Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services
shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievements of the hospital,
they could not have been reached without the support of local authorities. Jiarun hospital has voluntarily paid income tax of $919
and $864 for the three months ended March 31, 2017 and 2016, respectively to support the local tax bureau's economical obligations.
Income from Operations and Net income
Income from Operations was $1,591,693 for the
three months ended March 31, 2017, as compared with operating income of $1,360,169 for the three months ended March 31, 2016.The
Company’s net income for the three months ended March 31, 2017 was $1,587,844 representing an increase of $227,270 or 17
%, over $1,360,574 for the three months ended March 31, 2016. The increases in income from operations and net income for the three
months ended March 31, 2017 were primarily due to aforementioned changes in operating revenue and operating expenses
Liquidity and Capital Resources
The accompanying financial statements have
been prepared for the company to continue as a going concern which contemplates, among other things, the realization of assets
and satisfaction of liabilities in the ordinary course of business.
As of March 31, 2017, the Company had $245,387
of cash and cash equivalents.
We are presently able to meet our obligations
as they come due. As of March 31, 2017, we had non-controlling interest of $5,557,232 and shareholders’ equity of $7,764,239.
We anticipate that our future liquidity requirements
will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources of funding
for such requirements are expected to be cash generated from operations and raising additional funds from the public offering and/or
debt financing. However, we can provide no assurances that we will be able to generate sufficient cash flow from operations and/or
obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.
Cash Flows and Capital Resources
We believe that we will generate cash flow
from our business, which, along with our available cash, will provide sufficient liquidity and financial flexibility. Our cash
flows are summarized below:
|
|
Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
Net cash provided by operating activities
|
|
|
215,967
|
|
|
|
1,354,162
|
|
Net cash used in investing activities
|
|
|
(591,799
|
)
|
|
|
(1,183,264
|
)
|
Net cash used in (provided by) financing activities
|
|
|
(272,425
|
)
|
|
|
(101,388
|
)
|
Effect of exchange rate fluctuation on cash and cash equivalents
|
|
|
2,982
|
|
|
|
(7,620
|
)
|
Net (increase) decrease in cash and cash equivalents
|
|
|
(645,275
|
)
|
|
|
61,890
|
|
Cash and cash equivalents, beginning of period
|
|
|
890,662
|
|
|
|
352,153
|
|
Cash and cash equivalents, ending of period
|
|
$
|
245,387
|
|
|
$
|
414,043
|
|
Net Cash provided by Operating Activities
For the three months ended March 31, 2017,
we had positive cash flow from operating activities of $215,967, a decrease of $1,138,195 from the same period of 2016, during
which we had cash flow from operating activities of $1,354,162. The net income for the three months ended March 31, 2017 increased
by $227,270 as compared to the three months ended March 31, 2016. The decrease in net cash used in operating activities was mainly
as a result of the increase of amounts due from related parties items totaling $2,509,555, which was due to the increase in the
deposit and the prepayment for decoration for the new outpatient building.
Net Cash Used in Investing Activities
Net cash used in investing activities for the
three months ended March 31, 2017 was $591,799, compared to net cash used in investing activities of $1,183,264 for the three months
ended March 31, 2016. The cash used in investing activities for the three months ended March 31, 2017 was mainly used for the purchase
of medical equipment.
Net Cash Provided by Financing Activities
Net cash used in financing activities for the
three months ended March 31, 2017 was $272,425, as compared to net cash used in financing activities of $101,388 for the three
months ended March 31, 2016. The cash used in financing activities for the three months ended March 31, 2017 was mainly provided
by proceeds from a short-term bank loan of $406,934 and used in payments on capital lease obligation of $679,359.
Trends, Events and Uncertainties
The China Ministry of Health, as well as other
related agencies, may change the prices we can charge for medical services, drugs and medications. We cannot predict the impact
of these proposed changes since the changes are not fully defined and we do not know whether such changes will ever be implemented
or when they may take effect.
In December 2014, our operations moved into
the new building. We have finished the decoration of the new building, and part of the expansion of medical facilities and purchases
of new medical equipment. The hospital will need more medical facilities to update the medical equipment and acquire one pharmaceuticals
wholesale and one medicine retail company. The new hospital building is being constructed by Harbin Baiyi Real Estate Development
Co., Ltd, which is owned by Junsheng Zhang, a related party. The building was leased from the related party by financial leasing.
The price of the Leasing Agreement referred to the local market price and audited by the auditor. The Leasing Agreement terms consist
of 30 payments. Each payment will be made on an annual basis when 7 million RMB per payment will be paid upfront for each leasing
period. The first payment was made on September 1
st
, 2014. At the end of the leasing period, a final payment will be
made to settle the total leasing amount. Both parties agreed for the leasee to pay 3 million RMB as deposit at the execution of
the Leasing Agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%,
which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the
ownership of the lease item will be transferred to the Jiarun.
We plan to acquire other hospitals and companies
involved in the healthcare industry in the PRC using cash and shares of our common stock. Substantial capital may be needed for
these acquisitions and we may need to raise additional funds through the sale of our common stock, debt financing or other arrangements.
We do not have any commitments or arrangements from any person to provide us with any additional capital. Additional capital may
not be available to us, or if available, on acceptable terms, in which case we would not be able to acquire other hospitals or
businesses in the healthcare industry.
Other than the factors listed above we do not
know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales
or revenues or income from continuing operations. Our business is not seasonal in nature.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet items reasonably likely to
have a material effect on our financial condition.
MANAGEMENT
Directors and Executive Officers
The following table sets forth the name, age and position of each
of our directors and executive officers:
Directors and Executive Officers*
|
|
Age
|
|
Position/Title
|
Junsheng Zhang
|
|
49
|
|
President, Chairman of the Board and Director
|
Lihua Sun
|
|
52
|
|
Chief Executive Officer and Director
|
Xuewei Zhang
|
|
30
|
|
Chief Financial Officer and Director
|
Yanhui Xing
|
|
33
|
|
Director
|
*
|
|
The business address for each of the directors and executive officers is 1st - 7th
Floor, Industrial and Commercial Bank Building, Xingfu Street, Hulan Town, Hulan District, Harbin City, Heilongjiang Province,
China 150025.
|
Junsheng Zhang, age 49, is our founder and
has served as our president and director since Feb 2006. Mr. Zhang was the co-founders of Jiarun Pharmacy, a retail company, and
Dahua Medical Co., Ltd (Wholesale provider), From 2003 to 2011, Mr. Zhang served as President and Chief Executive Officer of Dahua
Medical Ltd, a whole sale shop owned by Mr. Zhang. Mr. Zhang served as General Manager of Dongtai Medical Ltd from 1990 to 2003.
Mr. Zhang provides hands-on leadership, strategic direction and operations management with a focus on business development, exceptional
quality patient care and fiscal accountability. The right candidate was display high personal integrity, positivity and the ability
to operate effectively under pressure. Was a hand on self-starter who can assume broad responsibility in a dynamic, challenging
healthcare environment Mr. Zhang received a bachelor's degree in Traditional Chinese Medicine in China and an EMBA from Peking
University From Mr. Zhang’s experience and management skill should serve as a director.
Ms. Lihua Sun, age 52, is our Chief Executive
Officer and Director since Feb 2006. Ms. Sun is one of the cofounder of Jiarun Hospital, accountability for hospital operations,
budget development, analysis and oversight; marketing including volume growth/program development; FTE management; expense control;
policy and procedure development and implementation; and process development to facilitate regulatory compliance. She has more
than 30 years in the healthcare industry. She has been the former General Manager of Ankang Medicine in Hulan district and a Director
of Heilongjiang Dahua Medicine Co., Ltd. From Ms. Sun’s experience and management skill should serve as a director.
Miss. Xuewei Zhang, age-30 is our Chief Financial
Officer and Director since 2012, in 2009 Miss. Zhang served as finance manager of Jiarun Hospital. She earned a Bachelor degree
in Business Studies from University of Exeter. During her position performance, the chief financial officer was trained by Harbin
Humankind Biology Technology Co., Limited finance department, learned that reports financial statements under U.S. GAAP and was
involved in its proposed U.S. initial public offering, including preparing U.S. GAAP financial statements and quarterly and annually
fillings preparation. From 2009 to 2011, CFO learned U.S. GAAP, Securities Exchange Act 1934, Securities Act 1933, Regulation S-K
and Regulation S-X. In 2009, CFO served as the finance manager, served in progressive managerial roles in accounting management,
strategic planning and company control, have well knowledge about the hospital operation situation. From Miss. Zhang’s international
business study and US GAAP and SEC training experienced, she was designed to serve as a director and CFO.
Miss. Yanhui Xing, age-33, is our director
since 2012. Miss Xing served as the CEO assistant in Eden Hall Global Capital Co., Ltd, which is a financial advisor firm from
2010 until now. From 2007 to 2010, Miss Xing served as CFO assistant in Gfort. From 2006 to 2007, Miss Xing served as Finance manager
in Green Island Limited in New Zealand, from 2003-2004, Miss Xing served as Finance manager in Fresh and Natural Ltd in New Zealand.
Miss Xing earned Master degree of Banking and Bachelor degree in Accounting. From Miss. Xing’s accounting, financial advisory
experiences, international studies and IPO experience and management skills, she should serve as a director.
Our Chief Executive Officer and Director, Lihua
Sun is wife of Junsheng Zhang, our President and Director.
Our Chief Financial Officer and Director, Xuewei
Zhang, is daughter of Junsheng Zhang, Chairman and Director.
Legal Proceedings Involving Officers
and Directors
To our knowledge, during the last ten years, none of our directors
and executive officers (including those of our subsidiaries) has:
|
¨
|
Had
a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either
at the time of the bankruptcy or within two years prior to that time.
|
|
¨
|
Been
convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor
offenses.
|
|
¨
|
Been
subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities
or banking activities.
|
|
¨
|
Been
found by a court of competent jurisdiction (in a civil action), the SEC, or the Commodities Futures Trading Commission to have
violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.
|
|
¨
|
Been
the subject to, or a party to, any sanction or order, not subsequently reverse, suspended or vacated, of any self-regulatory organization,
any registered entity, or any equivalent exchange, association, entity or organization that has disciplinary authority over its
members or persons associated with a member.
|
During the fiscal year of 2016, our Board of Directors had one
meeting, including meetings that were held by means of a conference telephone call, but excluding actions taken by unanimous written
consent.
Board Committees
Audit Committee
We have not yet appointed an audit committee. At the present
time, we believe that the members of Board of Directors are collectively capable of analyzing and evaluating our financial statements
and understanding internal controls and procedures for financial reporting. We do, however, recognize the importance of good
corporate governance and intend to appoint an audit committee comprised entirely of independent directors, including at least
one financial expert, in the near future.
Compensation Committee
We do not presently have a compensation committee. Our board
of directors currently acts as our compensation committee.
Nominating Committee
We do not presently have a nominating committee. Our board
of directors currently acts as our nominating committee.
Code of Ethics
We do not presently have a code of ethics. However, we intend to
adopt such a code of ethics in the future.
Board Leadership Structure and Role in Risk Oversight
Junsheng Zhang is our President and Chairman.
We do not have any independent directors. The Board believes that the Company’s Chairman is best situated to serve as Chairman
of the Board because he is the director most familiar with our business and industry and the director most capable of identifying
strategic priorities and executing our business strategy. In addition, having a single leader eliminates the potential for confusion
and provides clear leadership for the Company. We believe that this leadership structure has served the Company well.
Our Board of Directors is primarily responsible
for overseeing our risk management processes. The Board of Directors receives and reviews periodic reports from management,
auditors, legal counsel, and others, as considered appropriate regarding the Company’s assessment of risks. The Board of
Directors focuses on the most significant risks facing us and our general risk management strategy, and also ensures that risks
undertaken by us are consistent with the Board of Directors’ appetite for risk. While the Board of Directors oversees the
Company, our management is responsible for day-to-day risk management processes. We believe this division of responsibilities is
the most effective approach for addressing the risks facing the Company and that our board leadership structure supports this approach.
EXECUTIVE COMPENSATION
Summary Compensation Table
The following table sets forth information with respect to compensation
paid by us to our officers from the fiscal years ended 2015 and 2016, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
|
Non-qualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Deferred
|
|
|
All
|
|
|
|
|
Name and
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
Plan
|
|
|
Comp.
|
|
|
Other
|
|
|
|
|
Principal
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Awards
|
|
|
Awards
|
|
|
Comp.
|
|
|
Earnings
|
|
|
Comp.
|
|
|
Total
|
|
Position
|
|
Year
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
Junsheng Zhang
|
|
2015
|
|
|
6,743
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6,743
|
|
Chairman,
|
|
2016
|
|
|
6,321
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6,321
|
|
Lihua Sun
|
|
2015
|
|
|
6,358
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6,358
|
|
CEO/Director
|
|
2016
|
|
|
6,291
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6,291
|
|
Amounts of compensation for 2016
and 2015, reported in the table above, represent accrued compensation. The manner and timing of payments of the accrued compensation
will depend on the future financial conditions of the Company.
Refer to the Notes to Financial Statements
for more information.
Outstanding Equity Awards
No individual grants of stock options or other equity incentive
awards have been made to any executive officer or any director since our inception.
Employment Contracts, Termination of Employment, Change-in-Control
Arrangements
We have not entered into any employment or other contracts or arrangements
with our executive officers. There are no compensation plans or arrangements, including payments to be made by us, with respect
to our officers, directors or consultants that would result from the resignation, retirement or any other termination of such directors,
officers or consultants from us. There are no arrangements for directors, officers, employees or consultants that would result
from a change-in-control.
Compensation of Directors
We have no formal plan for compensating our
directors for their services in their capacity as directors. Directors are entitled to reimbursement for reasonable travel and
other out-of-pocket expenses incurred in connection with attendance at meetings of our Board of Directors. The Board of Directors
may award special remuneration to any director undertaking any special services on behalf of JRSIS HEALTH CARE CORPORATION other
than services ordinarily required of a director.
The following table sets forth certain information
regarding our shares of common stock beneficially owned as of the date hereof for (i) each stockholder known to be the beneficial
owner of 5% or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive
officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly
or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial
ownership at any time within 60 days through an exercise of stock options or warrants or otherwise. Unless otherwise indicated,
voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely
by the beneficial owner or shared by the owner and the owner’s spouse or children.
For purposes of this table, a person or group
of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to
acquire within 60 days as of the date hereof. For purposes of computing the percentage of outstanding shares of our common stock
held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60
days of the Closing Date is deemed to be outstanding, but is not deemed to be outstanding for the purpose of computing the percentage
ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission
of beneficial ownership.
The percentage ownership information shown
in the table below is calculated based on 13,915,000 shares of our common stock issued and outstanding as of June 30, 2017. We
do not have any outstanding options, warrants or other securities exercisable for or convertible into shares of our common stock.
|
|
|
|
Amount and
Nature
|
|
|
|
|
Title of
|
|
|
|
of Beneficial
|
|
|
|
|
Class
|
|
Name of Beneficial Owner
|
|
Ownership
|
|
|
Percentage
|
|
Common Stock
|
|
Junsheng Zhang
|
|
|
11,160,000
|
|
|
|
80.20
|
%
|
|
|
President, Chairman of the board.
|
|
|
Direct
|
|
|
|
|
|
Common Stock
|
|
Sujuan Peng
|
|
|
252,000
|
|
|
|
1.81
|
%
|
|
|
|
|
|
Direct
|
|
|
|
|
|
Common Stock
|
|
Yanhua Xing
|
|
|
588,000
|
|
|
|
4.23
|
%
|
|
|
|
|
|
Direct
|
|
|
|
|
|
|
|
All Officers and Directors as a Group
|
|
|
12,000,000
|
|
|
|
86.24
|
%
|
*Note: On November 25, 2015, Weiguang Song transferred all
252,000 shares to Sujuan Peng. As of June 30, 2017, Sujuan Peng is holding 252,000 shares.
As a result, our executive officers, directors and affiliated persons
will have significant influence to:
|
·
|
Elect or defeat the election of our directors;
|
|
·
|
Amend or prevent amendment of our articles of incorporation
or bylaws;
|
|
·
|
Effect or prevent a merger, sale of assets or other corporate
transaction; and
|
|
·
|
Affect the outcome of any other matter submitted to the
stockholders for vote.
|
Moreover, because of the significant ownership position held by
our insiders, new investors will not be able to effect a change in the Company’s business or management, and therefore,
shareholders would be subject to decisions made by management and the majority shareholders.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Other than the stock transactions discussed below, we have not entered
into any transaction nor are there any proposed transactions in which any director, executive officer, shareholder of the company
or any member of the immediate family of any of the foregoing had or is to have a direct or indirect material interest.
On December 20, 2013, we acquired One Hundred Percent (100%) of
the issued and outstanding capital stock of JRSIS Health Care Limited, a privately held Limited Liability Company registered in
the British Virgin Islands (“JHCL”) for Twelve Million (12,000,000) shares of our common stock paid to the three shareholders
of JHCL. Only one of the three shareholders of JHCL is also our officer and director and the shares were issued as follows:
Junsheng Zhang
|
|
11,160,000 shares
|
|
|
|
Yanhua Xing
|
|
588,000 shares
|
|
|
|
Weiguang Song
|
|
252,000 shares
|
On November 25, 2015, Weiguang Song transferred all 252,000 shares
to Sujuan Peng. As of June 30, 2017, Sujuan Peng is holding 252,000 shares.
The Company has entered into a financial leasing agreement for its
new hospital buildings with Harbin Baiyi Real Estate Development Co., Ltd. The Leasing terms consist of principal plus interest
of 30 payments. The annually rent is approximately 7 million RMB.
PLAN OF DISTRIBUTION
We are registering 1,589,000 shares of common
stock for resale by the selling stockholders from time to time after the date of this prospectus. We will not receive any of the
proceeds from the sale by the selling stockholders of the shares of common stock. We will bear all fees and expenses incident to
our obligation to register the shares of common stock.
The selling stockholders may sell all or a
portion of the shares of common stock held by them and offered hereby from time to time directly or through one or more underwriters,
broker-dealers or agents. If the shares of common stock are sold through underwriters, broker-dealers or agents, the selling stockholders
will be responsible for underwriting discounts or commissions or agent's commissions. The selling security holders will offer and
sell our common stock at a fixed price of $0.5725 per share, until a public market emerges for our common stock and, thereafter,
at prevailing market prices. These sales may be affected in transactions, which may involve crosses or block transactions, pursuant
to one or more of the following methods:
• On any national securities exchange
or quotation service on which the securities may be listed or quoted at the time of sale;
• In the over-the-counter market;
• In transactions otherwise than on these
exchanges or systems or in the over-the-counter market;
• Through the writing or settlement of
options, whether such options are listed on an options exchange or otherwise;
• Ordinary brokerage transactions and
transactions in which the broker-dealer solicits purchasers;
• Block trades in which the broker-dealer
will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
• Purchases by a broker-dealer as principal
and resale by the broker-dealer for its account;
• An exchange distribution in accordance
with the rules of the applicable exchange;
• Privately negotiated transactions;
• Short sales made after the date the
Registration Statement is declared effective by the Commission;
• Broker-dealers may agree with the selling
security holders to sell a specified number of such shares at a stipulated price per share;
• A combination of any such methods of
sale; and
• Any other method permitted pursuant
to applicable law.
The selling stockholders may also sell shares
of common stock under Rule 144 promulgated under the Securities Act, if available, rather than under this prospectus. In addition,
the selling stockholders may transfer the shares of common stock by other means not described in this prospectus. If the selling
stockholders effect such transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such
underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling
stockholders or commissions from purchasers of the shares of common stock for whom they may act as agent or to whom they may sell
as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess
of those customary in the types of transactions involved). In connection with sales of the shares of common stock or otherwise,
the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the
shares of common stock in the course of hedging in positions they assume. The selling stockholders may also sell shares of common
stock short and deliver shares of common stock covered by this prospectus to close out short positions and to return borrowed shares
in connection with such short sales. The selling stockholders may also loan or pledge shares of common stock to broker-dealers
that in turn may sell such shares.
The selling stockholders may pledge or grant
a security interest in some or all of the notes, warrants or shares of common stock owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant
to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest
as selling stockholders under this prospectus. The selling stockholders also may transfer, donate and pledge the shares of common
stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.
To the extent required by the Securities Act,
the selling stockholders and any broker-dealer participating in the distribution of the shares of common stock may be deemed to
be "underwriters" within the meaning of the Securities Act, and any commission paid, or any discounts or concessions
allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time
a particular offering of the shares of common stock is made, a prospectus supplement, if required, will be distributed, which will
set forth the aggregate amount of shares of common stock being offered and the terms of the offering, including the name or names
of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders
and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.
The selling security holders may also sell
shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.
In general, under Rule 144 as currently in
effect, a person who is not one of our affiliates and who is not deemed to have been one of our affiliates at any time during the
three months preceding a sale and who has beneficially owned shares of our common stock that are deemed restricted securities for
at least six months would be entitled after such six-month holding period to sell the common stock held by such person, subject
to the continued availability of current public information about us (which current public information requirement is eliminated
after a one-year holding period).
A person who is one of our affiliates, or has
been an affiliate of ours at any time during the three months preceding a sale, and who has beneficially owned shares of our common
stock that are deemed restricted securities for at least six months would be entitled after such six-month holding period to sell
his or her securities, provided that he or she sells an amount that does not exceed 1% of the number of shares of our common stock
then outstanding, or 200,000 shares immediately after this offering (or, if our common stock is listed on a national securities
exchange, the average weekly trading volume of the shares during the four calendar weeks preceding the filing of a notice on Form
144 with respect to the sale), subject to the continued availability of current public information about us, compliance with certain
manner of sale provisions, and the filing of a Form 144 notice of sale if the sale is for an amount in excess of 5,000 shares or
for an aggregate sale price of more than $50,000 in a three-month period.
Rule 144 is not available for resale of restricted
securities of shell companies or former shell companies until one year elapses from the time that such company is no longer considered
a shell company.
Under the securities laws of some states, the
shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some
states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or
an exemption from registration or qualification is available and is complied with.
There can be no assurance that any selling
stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of which this
prospectus forms a part.
The selling stockholders and any other person
participating in such distribution will be subject to applicable provisions of the Exchange Act, including, without limitation,
to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the
shares of common stock by the selling stockholders and any other participating person. To the extent applicable, Regulation M
may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making
activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares of common
stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock.
We will pay all expenses of the resale registration
of the shares of common stock, including, without limitation, SEC filing fees and expenses of compliance with state securities
or "blue sky" laws; provided, however, a selling stockholder will pay all underwriting discounts and selling commissions,
if any.
Once sold under the resale registration statement,
of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands of persons other than
our affiliates.
PRINCIPAL AND SELLING STOCKHOLDERS
This prospectus covers offers and sales of
up to 1,589,000 shares of our common stock which may be offered from time to time by the selling stockholder identified in this
prospectus.
The table below identifies each selling stockholder
and shows the number of shares of common stock beneficially owned by the selling stockholder before and after this offering, and
the numbers of shares offered for resale by the selling stockholder. Our registration of these shares does not necessarily mean
that each such selling stockholder will sell all or any of its shares of common stock. We assume that all shares covered by this
prospectus will be sold by each such selling stockholder and that no additional shares of common stock will be bought or sold by
the selling stockholder. No estimate can be given as to the number of shares that will be held by each such selling stockholder
after completion of this offering because each such selling stockholder may offer some or all of the shares and, to our knowledge,
there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares.
The following table sets forth the name of
each selling stockholder, and, if applicable, the nature of any position, office, or other material relationship which the selling
stockholder has had, within the past three years, with us or with any of our predecessors or affiliates, the amount of shares of
our common stock beneficially owned by such stockholder before the offering, the amount being offered for the stockholder’s
account, and the amount to be owned by such stockholder after completion of the offering.
Name of Selling
Stockholder and
Position, Office or
Material Relationship
with JRSIS HEALTH
CARE
|
|
Common Shares
owned by the Selling
|
|
|
Percent
beneficially
owned before
|
|
|
Total Shares to
be Registered
Pursuant
|
|
|
Number of Shares Owned by
Selling Stockholder After Offering
and Percent of Total Issued and
Outstanding)
|
CORPORATION
|
|
Stockholder
|
|
|
Offering
|
|
|
to this Offering
|
|
|
# of Shares
|
|
|
% of Class
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liping Tang
|
|
|
64,000
|
|
|
|
|
|
|
|
64,000
|
|
|
-
|
|
|
|
|
Jun Li
|
|
|
14,000
|
|
|
|
|
|
|
|
14,000
|
|
|
-
|
|
|
|
|
Wenyan Li
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Fangqi Ding
|
|
|
14,000
|
|
|
|
|
|
|
|
14,000
|
|
|
-
|
|
|
|
|
Fangwei Ding
|
|
|
14,000
|
|
|
|
|
|
|
|
14,000
|
|
|
-
|
|
|
|
|
Yaohua Jiang
|
|
|
70,000
|
|
|
|
|
|
|
|
70,000
|
|
|
-
|
|
|
|
|
Xifeng Zhao
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Zhongqiang Wang
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Chenghua Sun
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Xiaohui Sun
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Ying Tang
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Guozhi Wang
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Liru Zhao
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Jie Yang
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Liqing Li
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Aihua Chu
|
|
|
6,000
|
|
|
|
|
|
|
|
6,000
|
|
|
-
|
|
|
|
|
Lidong Sun
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Ying Jiang
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Shujuan Zhong
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Xuemei Bao
|
|
|
6,000
|
|
|
|
|
|
|
|
6,000
|
|
|
-
|
|
|
|
|
Daiying Wu
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Bo Zhang
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Dan Yang
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Chunling Jing
|
|
|
8,000
|
|
|
|
|
|
|
|
8,000
|
|
|
-
|
|
|
|
|
Caihong Feng
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Yong Qi
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Shichun Zong
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Li Wang
(1)
|
|
|
12,000
|
|
|
|
|
|
|
|
12,000
|
|
|
-
|
|
|
|
|
Wenshui Zhao
(2)
|
|
|
40,000
|
|
|
|
|
|
|
|
40,000
|
|
|
-
|
|
|
|
|
Yongquan Li
(3)
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Yanyan Sheng
(4)
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Jie Liu
(5)
|
|
|
6,000
|
|
|
|
|
|
|
|
6,000
|
|
|
-
|
|
|
|
|
Yinghong Zhao
(6)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Haiyan Xu
(7)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Jingbo Xue
(8)
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Guifeng Wang
(9)
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Minghui Ouyang
(10)
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Fangfang Dong
(11)
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Zhennan Gao
(12)
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Weinan Li
(13)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Dongmei Wu
(14)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Hongxu Zhang
(15)
|
|
|
8,000
|
|
|
|
|
|
|
|
8,000
|
|
|
-
|
|
|
|
|
Zhongjie Chen
(16)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Xingming Li
(17)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Zhaojun Li
(18)
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Hang Ma
(19)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Gang Han
|
|
|
50,000
|
|
|
|
|
|
|
|
50,000
|
|
|
-
|
|
|
|
|
Zhiwei Zhou
|
|
|
50,000
|
|
|
|
|
|
|
|
50,000
|
|
|
-
|
|
|
|
|
Jianghua Ren
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Yigang Jiang
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Qingli Meng
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Yongfeng Guo
|
|
|
250,000
|
|
|
|
|
|
|
|
250,000
|
|
|
-
|
|
|
|
|
Dan Huang
|
|
|
60,000
|
|
|
|
|
|
|
|
60,000
|
|
|
-
|
|
|
|
|
Lanying Zhang
(20)
|
|
|
40,000
|
|
|
|
|
|
|
|
40,000
|
|
|
-
|
|
|
|
|
Chongqing Wang
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Pinxia Jin
(21)
|
|
|
100,000
|
|
|
|
|
|
|
|
100,000
|
|
|
-
|
|
|
|
|
Lihong Xing
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Shanchuan Ma
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Xin Yuan
|
|
|
30,000
|
|
|
|
|
|
|
|
30,000
|
|
|
-
|
|
|
|
|
Chunjuan Wu
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Xuelian Kong
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Jing Yu
(22)
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Jianbo Sha
|
|
|
8,000
|
|
|
|
|
|
|
|
8,000
|
|
|
-
|
|
|
|
|
Yonggang Hu
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Ding Li
|
|
|
40,000
|
|
|
|
|
|
|
|
40,000
|
|
|
-
|
|
|
|
|
Li Chen
|
|
|
40,000
|
|
|
|
|
|
|
|
40,000
|
|
|
-
|
|
|
|
|
Yongqiang Bai
|
|
|
100,000
|
|
|
|
|
|
|
|
100,000
|
|
|
-
|
|
|
|
|
Xinhua Zhang
|
|
|
100,000
|
|
|
|
|
|
|
|
100,000
|
|
|
-
|
|
|
|
|
Xiuyun Chen
(23)
|
|
|
6,000
|
|
|
|
|
|
|
|
6,000
|
|
|
-
|
|
|
|
|
Fangbing Mu
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Xinli Sun
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Wenlei Wu
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
Haoyuan Zhang
|
|
|
6,000
|
|
|
|
|
|
|
|
6,000
|
|
|
-
|
|
|
|
|
Xiying Ma
|
|
|
3,000
|
|
|
|
|
|
|
|
3,000
|
|
|
-
|
|
|
|
|
Hongying Zeng
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Pinggao Hu
|
|
|
30,000
|
|
|
|
|
|
|
|
30,000
|
|
|
-
|
|
|
|
|
Na Li
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Jie Zou
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Jisheng Yang
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
|
-
|
|
|
|
|
Xiaowei Chen
|
|
|
6,000
|
|
|
|
|
|
|
|
6,000
|
|
|
-
|
|
|
|
|
WU YUBEN
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Guoping Song
|
|
|
20,000
|
|
|
|
|
|
|
|
20,000
|
|
|
-
|
|
|
|
|
HU YANGMEI
|
|
|
10,000
|
|
|
|
|
|
|
|
10,000
|
|
|
-
|
|
|
|
|
Zezeng Yu
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
XING YANHUI
(24)
|
|
|
2,000
|
|
|
|
|
|
|
|
2,000
|
|
|
-
|
|
|
|
|
Total
|
|
|
1,589,000
|
|
|
|
|
|
|
|
1,589,000
|
|
|
|
|
|
|
|
Except as set forth below, the selling stockholder
has not held any position or office with us or any of our affiliates, nor has had any other material relationship (other than as
a purchaser of securities) with us or any of our affiliates or predecessors within the past three years. Furthermore, none of the
selling stockholders are a registered broker-dealer or an affiliate of a registered broker-dealer.
Material relationship which the selling security
holder
(1)
|
Li Wang is an employee of Jiarun
|
(2)
|
Wenshui Zhao is an employee of Jiarun
|
(3)
|
Yongquan Li is an employee of Jiarun
|
(4)
|
Yanyan Sheng is an employee of Jiarun
|
(5)
|
Jie Liu is an employee of Jiarun
|
(6)
|
Yinghong Zhao is an employee of Jiarun
|
(7)
|
Haiyan Xu is an employee of Jiarun
|
(8)
|
Jingbo Xue is an employee of Jiarun
|
(9)
|
Guifeng Wang is an employee of Jiarun
|
(10)
|
Minghui Ouyang is an employee of Jiarun
|
(11)
|
Fangfang Dong is an employee of Jiarun
|
(12)
|
Zhennan Gao is an employee of Jiarun
|
(13)
|
Weinan Li is an employee of Jiarun
|
(14)
|
Dongmei Wu is an employee of Jiarun
|
(15)
|
Hongxu Zhang is an employee of Jiarun
|
(16)
|
Zhongjie Chen is an employee of Jiarun
|
(17)
|
Xingming Li is an employee of Jiarun
|
(18)
|
Zhaojun Li is an employee of Jiarun
|
(19)
|
Hang Ma is an employee of Jiarun
|
(20)
|
Lanying Zhang is the sister of our Chairman of the company
|
(21)
|
Pinxia Jin is the cousin of our Chairman of the company
|
(22)
|
Jing Yu is an employee of Jiarun
|
(23)
|
Xiuyun Chen is an employee of Jiarun
|
(24)
|
Xing Yanhui is a member of our Board of Director.
|
DESCRIPTION OF CAPITAL STOCK
Common Stock
Our authorized capital stock consists of 100,000,000
shares of common stock, par value $0.001 per share.
The holders of our common stock:
|
·
|
Have equal ratable rights to dividends from funds legally
available therefore, when, as and if declared by our Board of Directors;
|
|
·
|
Are entitled to share ratably in all of our assets available
for distribution to holders of common stock upon liquidation, dissolution or winding up of our affairs;
|
|
·
|
Do not have pre-emptive, subscription or conversion rights
and there is no redemption or sinking fund provisions or rights; and
|
|
·
|
Are entitled to one non-cumulative vote per share on all
matters on which stockholders may vote.
|
The shares of common stock are not subject
to any future call or assessment and all have equal voting rights. There are no special rights or restrictions of any nature attached
to any of the common shares and they all rank at equal rate or “ pari passu,” each with the other, as to all benefits,
which might accrue to the holders of the common shares. All registered stockholders are entitled to receive a notice of any general
annual meeting to be convened by our Board of Directors.
At any general meeting, subject to the restrictions
on joint registered owners of common shares, on a showing of hands every stockholder who is present in person and entitled to vote
has one vote, and on a poll every stockholder has one vote for each shares of common stock of which he is the registered owner
and may exercise such vote either in person or by proxy. A simple majority vote by our shareholders is required to take action.
To the knowledge of our management, at the date hereof, our officers and directors are the only persons to exercise control, directly
or indirectly, over more than 10% of our outstanding common shares. See “Security Ownership of Certain Beneficial Owners
and Management.”
We refer you to our Articles of Incorporation
and Bylaws, copies of which were filed with the registration statement of which this prospectus is a part, and to the applicable
statutes of the State of Florida for a more complete description of the rights and liabilities of holders of our securities.
As of June 30, 2017, there were 13,915,000
shares of our common stock issued and outstanding held by 101 shareholders.
Preferred Stock
We do not have any preferred stock authorized, issued or outstanding.
Options, Warrants and Rights
There are no outstanding options, warrants, or rights to purchase
any of our securities.
Non-cumulative Voting
Holders of shares of our common stock do not
have cumulative voting rights, which means that the holders of more than 50% of the outstanding shares, voting for the election
of directors, can elect all of the directors to be elected, if they so choose, and, in such event, the holders of the remaining
shares will not be able to elect any of our directors.
Cash Dividends
The declaration of any future cash dividend
will be at the discretion of our Board of Directors and will depend upon our earnings, if any, our capital requirements and financial
position, our general economic and other pertinent conditions. It is our present intention not to pay any cash dividends in the
foreseeable future, but rather to reinvest earnings, if any, into our business.
Transfer Agent
Our stock transfer agent for our securities
is VStock Transfer, LLC, 77 Spruce Street, Suite 201Cedarhurst, NY 11516. Their telephone number is (212) 828-8436.
SHARES ELIGIBLE FOR FUTURE RESALE
Upon completion of this offering, based on
our outstanding shares as of June 30, 2017, we will have outstanding an aggregate of 13,915,000 shares of our common stock. Of
these shares, upon effectiveness of the registration statement of which this prospectus forms a part, the 1,589,000 shares covered
hereby will be freely transferable without restriction or further registration under the Securities Act.
The 12,000,000 restricted shares of common
stock to be outstanding after this offering are owned by our executive officers and directors, known as our “affiliates,”
and other shareholders, and may not be resold in the public market except in compliance with the registration requirements of the
Securities Act or under an exemption under Rule 144 of the Securities Act.
Rule 144
In general, under Rule 144 as currently in
effect, a person who is not one of our affiliates and who is not deemed to have been one of our affiliates at any time during the
three months preceding a sale and who has beneficially owned shares of our common stock that are deemed restricted securities for
at least six months would be entitled after such six-month holding period to sell the common stock held by such person, subject
to the continued availability of current public information about us (which current public information requirement is eliminated
after a one-year holding period).
A person who is one of our affiliates, or has
been an affiliate of ours at any time during the three months preceding a sale, and who has beneficially owned shares of our common
stock that are deemed restricted securities for at least six months would be entitled after such six-month holding period to sell
his or her securities, provided that he or she sells an amount that does not exceed 1% of the number of shares of our common stock
then outstanding, or 200,000, shares immediately after this offering (or, if our common stock is listed on a national securities
exchange, the average weekly trading volume of the shares during the four calendar weeks preceding the filing of a notice on Form
144 with respect to the sale), subject to the continued availability of current public information about us, compliance with certain
manner of sale provisions, and the filing of a Form 144 notice of sale if the sale is for an amount in excess of 5,000 shares or
for an aggregate sale price of more than $50,000 in a three-month period.
Rule 144 is not available for resale of restricted
securities of shell companies or former shell companies until one year elapses from the time that such company is no longer considered
a shell company.
UNDERWRITING
We are not engaging an underwriter to assist us in this offering.
This offering is being made solely through our officers and directors.
LEGAL MATTERS
We know of no existing or pending legal proceedings
against us, nor are we involved as a plaintiff in any proceeding or pending litigation. There are no proceedings in which any of
our directors, officers or any of their respective affiliates, or any beneficial stockholder, is an adverse party or has a material
interest adverse to our interest.
EXPERTS
No expert or counsel named in this prospectus
as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities being
registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingency
basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the Company,
nor was any such person connected with the Company as a promoter, managing or principal underwriter, voting trustee, director,
officer or employee.
Our financial statements for the period from
January 01, 2016 through December 31, 2016, included in this prospectus have been audited by Centurion ZD CPA Limited, as set forth
in their report included in this prospectus.
LEGAL REPRESENTATION
The validity of the issuance of the common
stock offered hereby will be jointly passed upon for us by our securities counsel South Milhausen, P.A. and William D. O’Neal,
Esq., included in the opinion letter filed as an exhibit to the Registration Statement of which this prospectus is a part.
WHERE YOU CAN FIND MORE INFORMATION
In accordance with the Securities Act of 1933,
we are filing with the SEC a registration statement on Form Post-Effective Amendment S-2, of which this prospectus is a part, covering
the securities being offering in this offering. As permitted by rules and regulations of the SEC, this prospectus does not contain
all of the information set forth in the registration statement. For further information regarding both our Company and the securities
in this offering, we refer you to the registration statement, including all exhibits and schedules, which you may inspect without
charge at the public reference facilities of the SEC’s Washington, D.C. office, 100 F Street, N.E., Washington, D.C. 20549,
on official business days during the hours of 10am and 3pm, and on the SEC Internet site at http:www.sec.gov. Information regarding
the operation of the public reference rooms may be obtained by calling the SEC at 1-800-SEC-0330.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
Insofar as indemnification for liabilities arising under the Securities
Act of 1933, as amended, may be permitted to our directors, officers or persons controlling us, we have been advised that it is
the Securities and Exchange Commission’s opinion that such indemnification is against public policy as expressed in such
act and is, therefore, unenforceable.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To: the Board of Directors and Stockholders
of JRSIS Health Care Corporation
We have audited the accompanying consolidated
balance sheets of JRSIS Health Care Corporation and subsidiaries (“the Company”) as of December 31, 2016 and 2015 the
related statements of operations, stockholders’ equity and cash flows for each of the years in the period ended December
31, 2016 and 2015. These financial statements are the responsibility of the Company’s management. Our responsibility is to
express an opinion on these financial statements based on our audit.
We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included
consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over
financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made
by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
basis for our opinion.
In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the consolidated financial position of JRSIS Health Care
Corporation as of December 31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended in
conformity with accounting principles generally accepted in the United States of America.
/s/ Centurion ZD CPA Limited
Centurion ZD CPA Limited
(fka DCAW (CPA) Limited)
Certified Public Accountants
Hong Kong, China
March 29, 2017
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN USD, EXCEPT SHARES)
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current Assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
890,662
|
|
|
$
|
352,153
|
|
Accounts receivable, net
|
|
|
3,335,500
|
|
|
|
2,009,469
|
|
Inventories
|
|
|
801,240
|
|
|
|
499,080
|
|
Other receivables
|
|
|
1,555
|
|
|
|
2,125
|
|
Prepayments
|
|
|
518,722
|
|
|
|
201,542
|
|
Amount due from related parties
|
|
|
1,804,987
|
|
|
|
1,080,236
|
|
Deferred expenses
|
|
|
64,967
|
|
|
|
63,034
|
|
Total current assets
|
|
|
7,417,633
|
|
|
|
4,207,639
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
23,274,180
|
|
|
|
22,447,911
|
|
Long term deferred expenses
|
|
|
164,676
|
|
|
|
252,138
|
|
Deposits for capital leases
|
|
|
846,101
|
|
|
|
828,131
|
|
Total assets
|
|
$
|
31,702,590
|
|
|
$
|
27,735,819
|
|
|
|
|
|
|
|
|
|
|
Liabilities and shareholders’ equity
|
|
|
|
|
|
|
|
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
743,660
|
|
|
$
|
352,789
|
|
Deposits received
|
|
|
5,751
|
|
|
|
6,666
|
|
Amount due to related parties
|
|
|
25,329
|
|
|
|
97,328
|
|
Other payable
|
|
|
77,973
|
|
|
|
78,307
|
|
Payroll payable
|
|
|
52,072
|
|
|
|
44,376
|
|
Capital lease obligations - current portion
|
|
|
2,313,038
|
|
|
|
1,881,200
|
|
Total current liabilities
|
|
|
3,217,823
|
|
|
|
2,460,666
|
|
|
|
|
|
|
|
|
|
|
Capital lease obligations
|
|
|
16,222,992
|
|
|
|
17,863,608
|
|
Other capital lease payable
|
|
|
574,921
|
|
|
|
-
|
|
Total liabilities
|
|
$
|
20,015,736
|
|
|
$
|
20,324,274
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
|
|
|
|
|
|
Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,915,000 issued and outstanding at December 31, 2016 and 2015, respectively
|
|
|
13,915
|
|
|
|
13,915
|
|
Additional Paid-in capital
|
|
|
1,132,423
|
|
|
|
1,132,423
|
|
Retained earnings
|
|
|
6,274,052
|
|
|
|
2,802,184
|
|
Other comprehensive income
|
|
|
(786,055
|
)
|
|
|
(260,669
|
)
|
Total shareholders’ equity of the Company
|
|
|
6,634,335
|
|
|
|
3,687,853
|
|
Non-controlling interest
|
|
|
5,052,519
|
|
|
|
3,723,692
|
|
Total shareholders’ equity
|
|
|
11,686,854
|
|
|
|
7,411,545
|
|
Total liabilities and shareholders’ equity
|
|
$
|
31,702,590
|
|
|
$
|
27,735,819
|
|
See notes to consolidated
financial statements
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE
INCOME
(AMOUNTS IN USD, EXCEPT SHARES)
|
|
For The Year Ended
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
Medicine
|
|
$
|
7,998,195
|
|
|
$
|
5,503,971
|
|
Patient services
|
|
|
10,120,550
|
|
|
|
6,368,432
|
|
Total revenue
|
|
|
18,118,745
|
|
|
|
11,872,403
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
Cost of medicine sold
|
|
|
4,882,316
|
|
|
|
3,331,264
|
|
Medical consumables
|
|
|
1,747,917
|
|
|
|
839,702
|
|
Salaries and benefits
|
|
|
2,861,888
|
|
|
|
1,876,362
|
|
Office supplies
|
|
|
378,691
|
|
|
|
351,353
|
|
Vehicle expenses
|
|
|
56,605
|
|
|
|
36,013
|
|
Utilities expenses
|
|
|
443,054
|
|
|
|
491,209
|
|
Advertising and promotion expenses
|
|
|
119,156
|
|
|
|
-
|
|
Interest expense
|
|
|
1,384,826
|
|
|
|
1,244,185
|
|
Professional fee
|
|
|
140,059
|
|
|
|
200,904
|
|
Depreciation
|
|
|
1,081,123
|
|
|
|
871,948
|
|
Total operating costs and expenses
|
|
|
13,095,635
|
|
|
|
9,242,940
|
|
Earnings from operations before other income and income taxes
|
|
|
5,023,110
|
|
|
|
2,629,463
|
|
Other income
|
|
|
934
|
|
|
|
9,321
|
|
Earnings from operations before income taxes
|
|
|
5,024,044
|
|
|
|
2,638,784
|
|
Income tax
|
|
|
4,059
|
|
|
|
2,604
|
|
Net income
|
|
|
5,019,985
|
|
|
|
2,636,180
|
|
Less: net income attributable to non-controlling interests
|
|
|
1,548,117
|
|
|
|
845,467
|
|
Net income attributable to the Company
|
|
$
|
3,471,868
|
|
|
$
|
1,790,713
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment attributable to non-controlling interests
|
|
|
(219,290
|
)
|
|
|
(118,209
|
)
|
Foreign currency translation adjustment attributable to the Company
|
|
|
(525,386
|
)
|
|
|
(274,714
|
)
|
Comprehensive income
|
|
$
|
4,275,309
|
|
|
$
|
2,243,257
|
|
Less: Comprehensive income attributable to non-controlling interests
|
|
|
1,328,827
|
|
|
|
727,258
|
|
Comprehensive income attributable to the Company
|
|
$
|
2,946,482
|
|
|
$
|
1,515,999
|
|
Basic and diluted earnings per share
|
|
$
|
0.2495
|
|
|
$
|
0.1293
|
|
Weighted average number of shares outstanding
|
|
|
13,915,000
|
|
|
|
13,850,244
|
|
See notes to consolidated
financial statements
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED STATEMENT OF SHARESHOLDERS’
EQUITY
(AMOUNTS IN USD, EXCEPT SHARES)
|
|
Common stock
|
|
|
Retained
|
|
|
Other
comprehensive
|
|
|
Additional
paid-in
|
|
|
Non-
Controlling
|
|
|
Total
Shareholders’
|
|
|
|
Quantity
|
|
|
Amount
|
|
|
Earnings
|
|
|
income
|
|
|
capital
|
|
|
Interest
|
|
|
equity
|
|
Balance at December 31, 2014
|
|
|
13,604,000
|
|
|
$
|
13,604
|
|
|
$
|
1,011,471
|
|
|
$
|
14,045
|
|
|
$
|
954,686
|
|
|
$
|
2,996,434
|
|
|
$
|
4,990,240
|
|
Net income
|
|
|
-
|
|
|
|
-
|
|
|
|
1,790,713
|
|
|
|
-
|
|
|
|
-
|
|
|
|
845,467
|
|
|
|
2,636,180
|
|
Stock Exchange Merger & Acquisition
|
|
|
311,000
|
|
|
|
311
|
|
|
|
-
|
|
|
|
-
|
|
|
|
177,737
|
|
|
|
-
|
|
|
|
178,048
|
|
Foreign currency translation adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(274,714
|
)
|
|
|
-
|
|
|
|
(118,209
|
)
|
|
|
(392,923
|
)
|
Balance at December 31, 2015
|
|
|
13,915,000
|
|
|
$
|
13,915
|
|
|
$
|
2,802,184
|
|
|
$
|
(260,669
|
)
|
|
$
|
1,132,423
|
|
|
$
|
3,723,692
|
|
|
$
|
7,411,545
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
-
|
|
|
|
-
|
|
|
|
3,471,868
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,548,117
|
|
|
|
5,019,985
|
|
Stock Exchange Merger & Acquisition
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(525,386
|
)
|
|
|
-
|
|
|
|
(219,290
|
)
|
|
|
(744,676
|
)
|
Balance at December 31, 2016
|
|
|
13,915,000
|
|
|
$
|
13,915
|
|
|
$
|
6,274,052
|
|
|
$
|
(786,055
|
)
|
|
$
|
1,132,423
|
|
|
$
|
5,052,519
|
|
|
$
|
11,686,854
|
|
See notes to consolidated financial statements
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN USD, EXCEPT SHARES)
|
|
For The Year Ended
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Cash Flows From Operating Activities
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5,019,985
|
|
|
$
|
2,636,180
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
1,081,123
|
|
|
|
871,948
|
|
Interest
|
|
|
1,384,826
|
|
|
|
1,244,185
|
|
Gain on disposal of fixed assets
|
|
|
-
|
|
|
|
(12,370
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
|
(1,523,067
|
)
|
|
|
(1,440,617
|
)
|
Inventories
|
|
|
(349,866
|
)
|
|
|
(341,698
|
)
|
Amount due from related parties
|
|
|
(827,802
|
)
|
|
|
(939,964
|
)
|
Prepayments and other current assets
|
|
|
(173,064
|
)
|
|
|
491,212
|
|
Accounts payable
|
|
|
432,616
|
|
|
|
80,102
|
|
Amount due to related parties
|
|
|
70,865
|
|
|
|
(812,162
|
)
|
Deposits received
|
|
|
(502
|
)
|
|
|
501
|
|
Accrued expenses and other current liabilities
|
|
|
(128,648
|
)
|
|
|
754,322
|
|
Net cash provided by operating activities
|
|
|
4,986,466
|
|
|
|
2,531,639
|
|
|
|
|
|
|
|
|
|
|
Cash Flows From Investing Activities
|
|
|
|
|
|
|
|
|
Purchases of fixed assets
|
|
|
(3,475,536
|
)
|
|
|
(5,153,796
|
)
|
Prepayment for fixed assets acquisition (Proceed from sales buyback )
|
|
|
(135,261
|
)
|
|
|
576,189
|
|
Proceeds from disposal of fixed assets
|
|
|
-
|
|
|
|
44,952
|
|
Net cash used in investing activities
|
|
|
(3,610,797
|
)
|
|
|
(4,532,655
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows From Financing Activities
|
|
|
|
|
|
|
|
|
Proceeds from shareholders
|
|
|
-
|
|
|
|
178,048
|
|
Payments on capital lease obligation
|
|
|
(3,298,131
|
)
|
|
|
(2,149,439
|
)
|
Payments to related parties
|
|
|
-
|
|
|
|
(1,099,730
|
)
|
Short-term bank loans
|
|
|
-
|
|
|
|
(465,579
|
)
|
Proceeds from finance lease
|
|
|
2,521,933
|
|
|
|
4,872,018
|
|
Net cash used in (provided by) financing activities
|
|
|
(776,198
|
)
|
|
|
1,335,318
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate fluctuation on cash and cash equivalents
|
|
|
(60,962
|
)
|
|
|
(28,634
|
)
|
Net (decrease)increase in cash and cash equivalents
|
|
|
538,509
|
|
|
|
(694,332
|
)
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of period
|
|
|
352,153
|
|
|
|
1,046,485
|
|
Cash and cash equivalents, ending of period
|
|
$
|
890,662
|
|
|
$
|
352,153
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
|
(4,059
|
)
|
|
|
(2,604
|
)
|
Cash paid for interest
|
|
|
(1,384,826
|
)
|
|
|
(1,244,185
|
)
|
See notes to consolidated financial statements
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 1. D
ESCRIPTION
OF
B
USINESS AND
O
RGANIZATION
JRSIS HEALTH CARE CORPORATION (the “Company”
or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The
general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States
and the State of Florida.
JRSIS HEALTH CARE LIMITED ("JHCL"),
formally named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British
Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue 50,000 shares of a single class each with
par value of $1.00 per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd
has changed its name to JRSIS HEALTH CARE LIMITED ("JHCL").
Runteng Medical Group Co., Ltd (“Runteng”)
is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up
to 10,000 shares with par value of HK$1 per share to its sole shareholder Ms. Yanhua Xing.
Harbin Jiarun Hospital Co., Ltd (“Jiarun”)
was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private
hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents
of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a 70% owned subsidiary of the Company.
JHCC, JHCL, Runteng and Jiarun are collectively
referred as the “Group”.
Reorganization
On December 23, 2012, in accordance with the
"Foreign Investment Enterprise Law" under the People’s Republic of China (“PRC”), Runteng and Jiarun
entered into an agreement that Runteng and the original owner of Jiarun, Junsheng Zhang should invest a total of RMB50,000,000
($7,936,508), in which Runteng and the original owner should contribute RMB35,000,000 ($5,555,556) or 70% and RMB15,000,000 ($2,380,952)
or 30% of the total capital, respectively. According to the Joint Venture Investment Agreement, Runteng has the obligation to pay
RMB35,000,000 ($5,555,556) within five years after the issuance of the joint venture business license. As of December 31, 2016,
Jiarun has received $1,081,000 from Runteng.
On March 7, 2013, JHCL acquired all 100 issued
and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng.
On June 1, 2013, Junsheng Zhang, the owner
of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In
which, the historical accumulated profit of Jiarun up to June 30, 2013 should be 100% attributed to Junsheng Zhang; the profit
generated from Jiarun after July 1, 2013 should be attributed to Runteng and Junsheng Zhang on the basis of 70% and 30%, respectively.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 1. D
ESCRIPTION
OF
B
USINESS AND
O
RGANIZATION (
C
ONTINUED)
On July 29, 2013, the Joint Venture Investment
Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin
City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of
Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint
Venture prescribe duration of operation of Jiarun is twenty years.
On October 3, 2013, Ms. Yanhua Xing transferred
23,275 JHCL shares to Mr. Junsheng Zhang, 23,225 JHCL shares to Ms. Chunlan Tang, and 1,050 JHCL shares to Mr. Weiguang Song.
On November 8, 2013, Ms. Chunlan Tang transferred
all 23,225 JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings 46,500 JHCL shares.
On December 20, 2013, a share exchange agreement
was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to
issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in
exchange for 100% of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC
a total of 50,000 shares of the ordinary share of JHCL which represents 100% of the issued and outstanding shares of JHCL. JHCL
shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and assets of JHCL as now or hereafter
existing, including all business and assets of any and all subsidiaries of JHCL, including 70% ownership interest in Jiarun.
On July 8, 2014, Jiarun obtained joint venture
business license. Runteng has already completed cooperation restructuring. Up to completion of the legal structures, Jiarun are
compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.
Before and after the reorganization mentioned
above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the
other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well
as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and
rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by
Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization
transactions are considered as a series of transactions between the parties under common control and did not establish a new basis
in the assets and liabilities of the Operating Subsidiary.
During the reorganization, JHCC, JHCL, Runteng
and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization
accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests
accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements
as if the current structure existed since inception.
30% of Jiarun hospital interest held by Junsheng
Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest
in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying
to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 1, 2013, the
comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively,
from July 1, 2013.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
The consolidated financial statements have
been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP").
|
B.
|
Principles
of consolidation
|
The consolidated financial statements include
the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. Non-controlling interest
is reported in the consolidated financial position within equity, separately from the Company’s equity and that net income
or loss and comprehensive income or loss are attributable to the Company’s and the non-controlling interest.
The preparation of audited consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the
reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information
available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject
to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated
useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes
to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
|
D.
|
Functional
currency and foreign currency translation
|
JHCC and JHCL’s functional currency is
the United States dollar (“US$”). Runteng’s functional currency is the Hong Kong dollar (“HK$”).
The functional currency of Jiarun is the Renminbi (“RMB”).
The Company’s reporting currency is US$.
Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and
expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical
rates. Translation adjustments are reported in other comprehensive income.
|
E.
|
Concentration
of Credit Risk
|
Financial instruments that potentially subject
the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business
activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified
customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the years ended December
31, 2016 and 2015, no customer accounted for more than 10% of net revenue. As of December 31, 2016and 2015, 1 and 1 customer accounted
for more than 5% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial
strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible
accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
|
F.
|
Cash
and cash equivalents
|
Cash and cash equivalents include all cash,
deposits in banks and other liquid investments with initial maturities of three months or less.
Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts
is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable.
The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic
conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential
for recovery is considered remote.
Inventories, consisting principally of medicines,
are stated at the lower of cost or market using the first-in, first-out method (“FIFO”). This policy requires the Company
to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company
determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products.
|
I.
|
Construction
in progress
|
Construction in progress represents the new
hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction
in progress. No depreciation is provided in respect of construction in progress.
|
J.
|
Property
and equipment
|
Property and equipment are stated at cost.
Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized.
Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed,
the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected
in income.
Buildings and improvement
|
|
10-40 years
|
Medical equipment
|
|
5-15 years
|
Transportation instrument
|
|
5-10 years
|
Office equipment
|
|
5-10 years
|
Electronic equipment
|
|
5-10 years
|
Software
|
|
5-10 years
|
Operating lease
Leases where substantially all the rewards
and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including
scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive
income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are
recognized as expense when the achievement of the specified target is considered probable.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
Capital lease
Leases which substantially transfer all of
the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities
are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present
value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their
estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and
interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements
are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.
|
L.
|
Fair
Value Measurement
|
The Company applies the provisions of ASC Subtopic
820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements
of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework
for measuring fair value and expands disclosures about fair value measurements.
Fair value is defined as the price that would
be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company
considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants
would use when pricing the asset or liability.
ASC 820 establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair
value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority
to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy
are as follows:
Level 1: Unadjusted quoted prices
in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets
that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset
or liability;
Level 3: Prices or valuation techniques
that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market
activity).
There were no transfers between level 1, level
2 or level 3 measurements for the years ended December 31, 2016 and 2015.
Cash and cash equivalents, accounts receivable,
accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate
fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations
also approximates carrying value as they bear interest at current market rates.
|
M.
|
Segment
and geographic information
|
The Company is operating in one segment in
accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from
customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
The Company recognizes revenue when the amount
of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been
met for each of the Company’s activities as described below.
Medicine sales
Revenue from the sale of medicine is recognized
when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine,
ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all
of which generally occur when the patient receives the medicine.
Given the nature of this revenue source of
the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale
of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.
Patient Services
In accordance with the medical licenses of
Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology,
pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.
Patient service revenue is recognized when
it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has
been provided to the patient and collection of the revenue is reasonably assured.
The Company provides services to both patients
covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient
services regardless of the coverage by social insurance.
Patients who are not covered by social insurance
are liable for the total cost of medical treatment.
|
·
|
For
out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects
payment when the patient checks out from the hospital, which is the same day the services are provided.
|
|
·
|
For
in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’
symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient
and records the payment as deposits received.
|
During the in-patient services period, the
Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The
Company records these transactions based on daily reports generated by the respective medical department. When medical services
exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.
When patients check out from the hospital,
the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients.
In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required
to be paid in full at checkout.
Patients covered by social insurance will receive
a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement
process.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
|
N.
|
Revenue
recognition (continued)
|
Settlement process
The Company is a registered medical service
vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social
Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical
Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are
covered by social insurance agencies.
|
·
|
The
Company records patients’ information in the social insurance system at check in. The system determines the covered portion
and amounts based on the information input to the system.
|
|
·
|
At
the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from
the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have
made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.
|
|
·
|
The
Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their
review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance
agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following
the approval.
|
The Company adopts FASB ASC Topic 740, “Income
Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized
for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting
amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences
are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the
amount expected to be realized.
In July 2006, the FASB issued FIN 48(ASC 740-10),
Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions
to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax
positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial
reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not
threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.
The application of tax laws and regulations
is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change
as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the
actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities
or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
As a result of the implementation of FIN 48
(ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards
established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity
as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated
financial statements.
Enterprise income tax is defined under the
Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises
at a rate of 25% of their taxable income.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
|
O.
|
Income
taxes (continued)
|
Jiarun's medical services have been exempt
from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with
the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations"
Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services
shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievement of the hospital,
it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $4,059
and $2,604 for the years ended December 31, 2016 and 2015, respectively to support the local tax bureau's economical obligations.
Basic earnings per common share is computed
by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted
earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding for the periods presented.
The comparative figures have been reclassified
to conform to current year presentation.
|
R.
|
Recently
accounting pronouncements
|
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842), aimed at making leasing activities more transparent and comparable. The new standard requires substantially
all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including
today’s operating leases. For public business entities, the standard is effective for fiscal years beginning after December
15, 2018, including interim periods within those fiscal years. For all other entities, the standard is effective for fiscal years
beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early application
is permitted for all entities. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated
financial condition, results of operations and cash flows.
In March 2016, the FASB issued ASU No. 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).
The amendment in this update affect entities with transactions included within the scope of Topic 606, The scope of that Topic
includes entities that enter into contracts with customers to transfer goods or services (that are an output of the entity’s
ordinary activities) in exchange for consideration. The amendments are intended to improve the operability and understandability
of the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, The amendments
in ASU 2016-10 provide more detailed guidance, including additional implementation guidance and examples in the following key areas:
1) identifying performance obligations and 2) licenses of intellectual property. In May 2016, the FASB issued ASU No. 2016-12 a
proposed Update, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, on September
30, 2015. The amendments do not change the core principles of the standard, but clarify the guidance on assessing collectability,
presenting sales taxes, measuring noncash consideration and certain transition matters. This update becomes effective concurrently
with ASU No. 2014-09. The Company is currently evaluating the effect of this new standard, including the transition method, to
determine the impact on the Company's consolidated financial position, results of operations, cash flows, or related disclosures.
In October 2016, the FASB issued Accounting
Standards Update No. 2016-16, Income Taxes – Intra-Entity Transfers of Assets Other Than Inventory (ASU 2016-16). The standard
is intended to address diversity in practice and complexity in financial reporting, particularly for intra-entity transfers of
intellectual property. ASU 2016-16 will be effective for the Company beginning with the interim periods of fiscal 2018 and requires
the modified retrospective method of adoption. Early adoption is permitted. The Company is in the process of determining timing
of adoption and assessing the impact of ASU 2016-16 on its consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash (“ASU No. 2016-18”). ASU No. 2016-18 requires that a statement
of cash flows explain the change during the period in the total of cash, cash equivalents, restricted cash and restricted cash
equivalents. Therefore, amounts generally described as restricted cash should be included with cash and cash equivalents when reconciling
the beginning of period and end of period total amounts shown on the statement of cash flows. ASU No. 2016-18 is effective for
annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company elected to early
adopt ASU No. 2016-18 for the reporting period ending December 31, 2016 and was applied retrospectively. As a result of adoption
of ASU No. 2016-18, the Company no longer presents the changes within restricted cash in the consolidated statements of cash flows.
In January 2017, the FASB issued Accounting
Standards Board Update No. 2017-01: Business Combinations (Topic 805) - Clarifying the Definition of a Business (“ASU
2017-01”). The ASU clarifies the definition of business with the objective of adding guidance to assist entities with evaluating
whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 will be effective
for the Company’s fiscal year beginning January 1, 2018 and subsequent interim periods with prospective application with
impacts on the Company’s consolidated financial statements that may vary depending on each specific acquisition. Early adoption
is conditionally permitted.
We do not believe other recently issued but
not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position,
statements of operations and cash flows.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 3. Accounts Receivable, Net
|
|
December 31
|
|
|
|
2016
|
|
|
2015
|
|
Accounts receivable
|
|
$
|
3,359,619
|
|
|
$
|
2,035,271
|
|
Less: allowance for doubtful debts
|
|
|
24,119
|
|
|
|
25,802
|
|
|
|
$
|
3,335,500
|
|
|
$
|
2,009,469
|
|
The Company experienced nil bad debts during the years ended December
31, 2016 and 2015.
NOTE 4. Inventories
At December 31, 2016 and 2015, inventories
consist of the following:
|
|
December 31
|
|
|
|
2016
|
|
|
2015
|
|
Western medicine
|
|
$
|
548,724
|
|
|
$
|
377,989
|
|
Chinese herbal medicine
|
|
|
9,113
|
|
|
|
6,590
|
|
Medical material
|
|
|
241,630
|
|
|
|
111,808
|
|
Other material
|
|
|
1,773
|
|
|
|
2,693
|
|
|
|
$
|
801,240
|
|
|
$
|
499,080
|
|
NOTE 5. Prepayment
At December 31, 2016 and 2015, prepayment consists
of the following:
|
|
December 31
|
|
|
|
2016
|
|
|
2015
|
|
Deposits on medical equipment
|
|
$
|
221,083
|
|
|
$
|
38,952
|
|
Heating fees
|
|
|
86,515
|
|
|
|
92,535
|
|
Others
|
|
|
211,124
|
|
|
|
70,055
|
|
|
|
$
|
518,722
|
|
|
$
|
201,542
|
|
NOTE 6. Property and Equipment
At December 31, 2016 and 2015, property and equipment, at cost,
consist of:
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Transportation equipment
|
|
$
|
715,646
|
|
|
$
|
765,592
|
|
Medical equipment
|
|
|
9,282,026
|
|
|
|
7,047,404
|
|
Electrical equipment
|
|
|
1,310,927
|
|
|
|
799,045
|
|
Office equipment and other
|
|
|
93,283
|
|
|
|
87,110
|
|
Buildings
|
|
|
13,982,919
|
|
|
|
14,958,817
|
|
Software
|
|
|
137,028
|
|
|
|
87,957
|
|
Total fixed assets at cost
|
|
|
25,521,829
|
|
|
|
23,745,925
|
|
Accumulated depreciation
|
|
|
(2,247,649
|
)
|
|
|
(1,298,014
|
)
|
Total fixed assets, net
|
|
$
|
23,274,180
|
|
|
$
|
22,447,911
|
|
Depreciation expense was $1,081,123 and $871,948
for the years ended December 31, 2016 and 2015, respectively.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 7. Long Term Deferred Expenses
On May 7, 2015, July 3, 2015 and October 16,
2015, Jiarun entered into three lease agreements to lease medical equipment from Hair Finance Leasing (China) Co., Ltd.(“Hair”),
a third party, for a five-year period, in which Jiarun is required to pay consulting fee to Hair for the services provided over
the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as
deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses
$64,967 and $63,034 as of December 31, 2016 and 2015. The long-term deferred expenses were $164,676 and 252,138 as of December
31, 2016 and 2015.
The Company recorded consulting fee of $67,907
and $125,210 for the year ended December 31, 2016 and 2015, respectively.
NOTE 8. Capital Lease Obligations and Deposit
for Capital Leases
On June 5, 2013, Jiarun entered into a lease
agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd (“the Leasor”), which is owned
by Junsheng Zhang, a related party. The Leasing terms consist of principal plus 30 payments. Each payment will be made on an annual
basis when RMB7,000,000 per payment will be paid upfront for each leasing period. The first payment was made on September 1, 2014.
At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for Jiarun
to pay RMB3,000,000 as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement.
In accordance to accounting principles and treatment, this payment was booked as deposit in our accounts. The Leasor shall return
the premium for lease to Jiarun at expiration of this Contract, or pledge this deposit as part of rents for the last period or
periods in 2043. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s
Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to Jiarun.
The leasing agreement for our hospital building
contains the following provisions:
|
·
|
Rental
payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September.
|
|
·
|
An
option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the company.
|
|
·
|
A
guarantee by the company that the lessor will realize $nil, from selling the asset at the expiration of the lease This lease is
a capital lease because its term (30 years) exceeds 75% of the building’s estimated economic life. In addition, the present
value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295).
|
|
·
|
Accumulated
annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each
year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment
at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.
|
On September 1, 2014, October 22, 2014, March
26, 2015, May 7, 2015, July 3, 2015, October 16, 2015, April 6, 2016 and April 13, 2016 and November 25, 2016 Jiarun entered into
several lease agreements to lease medical equipment and elevator from three lease finance companies, which are all third parties,
for three to five year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company
was also required to pay deposits up front, which deposits will later be used to offset against the last quarterly payment. The
medical equipment and elevator will be transferred to Jiarun upon the completion of the agreement.
These leases have been classified as capital
leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and
equipment and construction in progress.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 8. Capital Lease Obligations and Deposit
for Capital Leases (Continued)
The future minimum lease payments for annual
capital lease obligation as of December 31, 2016 are as follows:
Year
|
|
Amounts
|
|
2017
|
|
$
|
2,313,038
|
|
2018
|
|
|
1,666,127
|
|
2019
|
|
|
1,473,960
|
|
Thereafter
|
|
|
13,082,905
|
|
Total
|
|
$
|
18,536,030
|
|
The Company recorded finance lease fees of
$1,344,867 and $1,217,539 for the years ended December, 2016 and 2015, respectively.
NOTE 9. Short-term Bank Loans
As of December 31, 2016, and 2015, the short-term
bank loans were $ nil and $ nil, respectively. The loans were primarily obtained from Harbin Bank with interest rate of 6.09% per
annum, from December 25, 2015 to December 24, 2016, for working capital and capital expenditure purposes. The interest expenses
were $26,212 and $33,967 for the year ended December 31, 2016 and 2015, respectively.
NOTE 10. Non-controlling Interests
Jiarun is the Company’s majority-owned
subsidiary which is consolidated in the Company’s financial statements with a non-controlling interest recognized. The Company
holds 70% interest of Jiarun as of December 31, 2016 and 2015.
As of December 31, 2016, and 2015, NCI in the
consolidated balance sheet was $5,052,519 and $3,732,692, respectively. For the year ended December 31, 2016, the comprehensive
income attributable to shareholders’ equity and NCI is $2,946,482 and $1,328,827 respectively. For the year ended December
31, 2015, the comprehensive income attributable to shareholders’ equity and NCIs is $1,515,999 and $727,258, respectively.
NOTE 11. Revenue
The Company’s revenue consists of medicine
sales and patient care revenue.
|
|
For the Year Ended December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Medicine:
|
|
|
|
|
|
|
Western medicine
|
|
$
|
6,207,470
|
|
|
$
|
4,283,342
|
|
Chinese medicine
|
|
|
1,493,283
|
|
|
|
1,057,953
|
|
Herbal medicine
|
|
|
297,442
|
|
|
|
162,676
|
|
Total medicine
|
|
$
|
7,998,195
|
|
|
$
|
5,503,971
|
|
|
|
|
|
|
|
|
|
|
Patient services:
|
|
|
|
|
|
|
|
|
Medical consulting
|
|
$
|
5,298,753
|
|
|
$
|
3,223,319
|
|
Medical treatment
|
|
|
4,588,582
|
|
|
|
2,982,636
|
|
Others
|
|
|
233,215
|
|
|
|
162,477
|
|
Total patient services
|
|
$
|
10,120,550
|
|
|
$
|
6,368,432
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
18,118,745
|
|
|
$
|
11,872,403
|
|
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 12. Income Tax Expense
The Company uses the asset-liability method
of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each files their taxes individually.
United States
JHCC is subject to the United States of America
Tax law at tax rate of 34%. No provision for the US federal income taxes has been made as the Company had no US taxable income
for the periods presented, and its earnings are permanently invested in PRC.
BVI
JHCL was incorporated in the BVI and, under
the current laws of the BVI, it is not subject to income tax.
Hong Kong
Runteng was incorporated in Hong Kong
and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and
income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%.
PRC
Jiarun's medical services have been exempt
from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with
the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations"
Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services
shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievement of the hospital,
it could not have been done without the support of local authorities, Jiarun has voluntarily paid income tax of $4,059 and $2,604
for the years ended December 31, 2016 and 2015, respectively to support the local tax bureau's economical obligations.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 13. Related Party Transactions
The following is the list of the related parties
to which the Group has transactions with:
(a) Junsheng Zhang, the Chairman of the Company
(b) Harbin Baiyi Real Estate Development Co.,
Ltd, owned by Junsheng Zhang
(c) Heilongjiang Dahua Medicine Wholesale Co.,
Ltd owned by Junsheng Zhang
(d) Harbin Jiarun Pharmacy Co., Limited owned
by Junsheng Zhang
(e) Heilongjiang Province Runjia Medical Equipment
Company Limited owned by Junsheng Zhang
(f) Jiarun Super Market Co., Ltd. owned by
Junsheng Zhang
(g) Harbin Qi-run pharmacy limited owned by
Junsheng Zhang
(h) Yanhua Xing and Weiguang Song, the former
shareholder of JHCL
Amount due from related parties
Amount due from related parties consisted of
the following as of the periods indicated:
|
|
December 31,
|
|
Name of related parties
|
|
2016
|
|
|
2015
|
|
Harbin Baiyi Real Estate Development Co., Ltd,
|
|
$
|
1,754,987
|
|
|
$
|
1,030,236
|
|
Junsheng Zhang
|
|
|
46,500
|
|
|
|
46,500
|
|
Yanhua Xing
|
|
|
2,450
|
|
|
|
2,450
|
|
Weiguang Song
|
|
|
1,050
|
|
|
|
1,050
|
|
|
|
$
|
1,804,987
|
|
|
$
|
1,080,236
|
|
Amount due from Baiyi was mainly represented
the deposit for the new outpatient building which was constructed by Baiyi. The Company signed a purchase agreement with Baiyi
to acquire the first to eight floor of a building which is under construction by Baiyi and expected to be completed in first-quarter
of 2016. The total amount for the purchased property is approximately RMB63,900,000 ($9,579,894). The Company had paid a deposit
of RMB10,000,000 ($1,439,932) was paid in 2016.
Amount due from Junsheng Zhang, Yanhua Xing
and Weiguang Song, who are the prior shareholders of JHCL, was mainly for the paid-in capital to be paid.
Amount due to related parties
Amount due to related parties consisted of
the following as of the periods indicated:
|
|
December 31,
|
|
Name of related parties
|
|
2016
|
|
|
2015
|
|
Heilongjiang Dahua Medicine Wholesale Co., Ltd
|
|
$
|
-
|
|
|
$
|
59,424
|
|
Heilongjiang Province Runjia Medical Equipment Co., Ltd
|
|
|
18,382
|
|
|
|
32,742
|
|
Harbin Qi-run pharmacy Co., Ltd
|
|
|
6,947
|
|
|
|
-
|
|
Junsheng Zhang
|
|
|
-
|
|
|
|
5,162
|
|
|
|
$
|
25,329
|
|
|
$
|
97,328
|
|
Amount due to Heilongjiang Dahua Medicine
Wholesale Co., Ltd., Harbin Qi-run Pharmacy Co., Ltd. and Heilongjiang Province Runjia Medical Equipment Company Limited were mainly
for the balance for purchase of medicine and medical material from these three companies.
Amounts due to Junsheng Zhang represented the
balance paid by Mr. Zhang for the daily operation of the company.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 13. Related Party Transactions (Continued)
Related parties’ transactions
Purchase of medicine and medical material from
related parties consisted of the following for the periods indicated:
|
|
For the Year ended December 31,
|
|
Name of related parties
|
|
2016
|
|
|
2015
|
|
Heilongjiang Dahua Medicine Wholesale Co., Ltd
|
|
$
|
520,182
|
|
|
$
|
658,768
|
|
Harbin Jiarun Pharmacy Co., Ltd
|
|
|
170,638
|
|
|
|
281,588
|
|
Heilongjiang Province Runjia Medical Equipment Co., Ltd
|
|
|
55,821
|
|
|
|
173,662
|
|
Harbin Qi-run pharmacy Co., Ltd
|
|
|
26,273
|
|
|
|
-
|
|
|
|
$
|
772,914
|
|
|
$
|
1,114,018
|
|
Deposits for capital leases and
Capital lease obligations
On June 5, 2013, Jiarun entered into a Lease
Agreement to lease new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang,
a related party. As of December 31, 2016, the company has balance of deposits for capital leases and capital lease obligations
of $431,980 and $13,896,989 respectively. As of December 31, 2015, the company has balance of deposits for capital leases and capital
lease obligations of $462,129 and $13,975,067 respectively.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 14. Basic and Diluted Earnings
Per Share
Basic net income per share is computed using
the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the
weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common
shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. The reconciliation of
the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations
is shown as follows:
|
|
December 31
|
|
|
|
2016
|
|
|
2015
|
|
Numerator:
|
|
|
|
|
|
|
Net income available to common stockholders
|
|
$
|
3,471,868
|
|
|
$
|
1,790,713
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Basic and diluted weighted-average number of shares outstanding
|
|
|
13,915,000
|
|
|
|
13,850,244
|
|
Net income per share:
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
$
|
0.2495
|
|
|
$
|
0.1293
|
|
NOTE 15. Contingencies and Commitment
Certain conditions may exist as of the date
the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when
one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities,
and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that
are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates
the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought
or expected to be sought. There was no contingency of this type as of December 31, 2016 and 2015.
If the assessment of a contingency indicates
that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated
liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss
contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. There was no
contingency of this type as of December 31, 2016 and2015.
Loss contingencies considered to be remote
by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
NOTE 16. Subsequent Events
The Management of the Company determined that
there were no reportable subsequent events to be disclosed.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN USD, EXCEPT SHARES)
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current Assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
245,387
|
|
|
$
|
890,662
|
|
Accounts receivable, net
|
|
|
3,345,358
|
|
|
|
3,335,500
|
|
Inventories
|
|
|
834,788
|
|
|
|
801,240
|
|
Other receivables
|
|
|
3,149
|
|
|
|
1,555
|
|
Prepayments
|
|
|
398,338
|
|
|
|
518,722
|
|
Amount due from related parties
|
|
|
4,408,193
|
|
|
|
1,804,987
|
|
Deferred expenses
|
|
|
65,473
|
|
|
|
64,967
|
|
Deposits for capital leases
|
|
|
262,946
|
|
|
|
-
|
|
Total current assets
|
|
|
9,563,632
|
|
|
|
7,417,633
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
23,962,577
|
|
|
|
23,274,180
|
|
Long term deferred expenses
|
|
|
149,589
|
|
|
|
164,676
|
|
Deposits for capital leases
|
|
|
589,738
|
|
|
|
846,101
|
|
Total assets
|
|
$
|
34,265,536
|
|
|
$
|
31,702,590
|
|
|
|
|
|
|
|
|
|
|
Liabilities and shareholders’ equity
|
|
|
|
|
|
|
|
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,414,502
|
|
|
$
|
743,660
|
|
Short-term bank loan
|
|
|
420,829
|
|
|
|
-
|
|
Deposits received
|
|
|
5,796
|
|
|
|
5,751
|
|
Amount due to related parties
|
|
|
121,757
|
|
|
|
25,329
|
|
Other payable
|
|
|
23,352
|
|
|
|
77,973
|
|
Payroll payable
|
|
|
57,786
|
|
|
|
52,072
|
|
Capital lease obligations - current portion
|
|
|
2,200,521
|
|
|
|
2,313,038
|
|
Total current liabilities
|
|
|
4,244,543
|
|
|
|
3,217,823
|
|
|
|
|
|
|
|
|
|
|
Capital lease obligations
|
|
|
16,130,228
|
|
|
|
16,222,992
|
|
Other capital lease payable
|
|
|
569,294
|
|
|
|
574,921
|
|
Total liabilities
|
|
$
|
20,944,065
|
|
|
$
|
20,015,736
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
|
|
|
|
|
|
Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,915,000 issued and outstanding at March 31, 2017 and December 31, 2016, respectively
|
|
|
13,915
|
|
|
|
13,915
|
|
Additional Paid-in capital
|
|
|
1,132,423
|
|
|
|
1,132,423
|
|
Retained earnings
|
|
|
7,385,543
|
|
|
|
6,274,052
|
|
Other comprehensive income
|
|
|
(767,642
|
)
|
|
|
(786,055
|
)
|
Total shareholders’ equity of the Company
|
|
|
7,764,239
|
|
|
|
6,634,335
|
|
Non-controlling interest
|
|
|
5,557,232
|
|
|
|
5,052,519
|
|
Total shareholders’ equity
|
|
|
13,321,471
|
|
|
|
11,686,854
|
|
Total liabilities and shareholders’ equity
|
|
$
|
34,265,536
|
|
|
$
|
31,702,590
|
|
See notes to consolidated financial statements
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME
(AMOUNTS IN USD, EXCEPT SHARES) (UNAUDITED)
|
|
Three Months Ended
March 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
Revenue:
|
|
|
|
|
|
|
Medicine
|
|
$
|
2,528,075
|
|
|
$
|
1,925,675
|
|
Patient services
|
|
|
2,982,737
|
|
|
|
2,482,956
|
|
Total revenue
|
|
|
5,510,812
|
|
|
|
4,408,631
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
Cost of medicine sold
|
|
|
1,650,466
|
|
|
|
1,106,181
|
|
Medical consumables
|
|
|
558,302
|
|
|
|
389,760
|
|
Salaries and benefits
|
|
|
814,366
|
|
|
|
682,590
|
|
Office supplies
|
|
|
119,302
|
|
|
|
81,806
|
|
Vehicle expenses
|
|
|
21,480
|
|
|
|
9,571
|
|
Utilities expenses
|
|
|
147,887
|
|
|
|
146,107
|
|
Advertising and promotion expenses
|
|
|
614
|
|
|
|
43,921
|
|
Interest expense
|
|
|
289,939
|
|
|
|
343,818
|
|
Professional fee
|
|
|
13,762
|
|
|
|
4,423
|
|
Depreciation
|
|
|
303,001
|
|
|
|
240,285
|
|
Total operating costs and expenses
|
|
|
3,919,119
|
|
|
|
3,048,462
|
|
Earnings from operations before other income and income taxes
|
|
|
1,591,693
|
|
|
|
1,360,169
|
|
Other income
|
|
|
(2,930
|
)
|
|
|
1,269
|
|
Earnings from operations before income taxes
|
|
|
1,588,763
|
|
|
|
1,361,438
|
|
Income tax
|
|
|
919
|
|
|
|
864
|
|
Net income
|
|
|
1,587,844
|
|
|
|
1,360,574
|
|
Less: net income attributable to non-controlling interests
|
|
|
476,353
|
|
|
|
420,273
|
|
Net income attributable to the Company
|
|
$
|
1,111,491
|
|
|
$
|
940,301
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment attributable to non-controlling interests
|
|
|
28,360
|
|
|
|
21,262
|
|
Foreign currency translation adjustment attributable to the Company
|
|
|
18,413
|
|
|
|
30,496
|
|
Comprehensive income
|
|
$
|
1,634,617
|
|
|
$
|
1,412,332
|
|
Less: Comprehensive income attributable to non-controlling interests
|
|
|
504,713
|
|
|
|
441,535
|
|
Comprehensive income attributable to the Company
|
|
$
|
1,129,904
|
|
|
$
|
970,797
|
|
Basic and diluted earnings per share
|
|
$
|
0.0799
|
|
|
$
|
0.0676
|
|
Weighted average number of shares outstanding
|
|
|
13,915,000
|
|
|
|
13,915,000
|
|
See notes to consolidated financial statements
JRSIS HEALTH CARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN USD, EXCEPT SHARES)
|
|
Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
Cash Flows From Operating Activities
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1,587,844
|
|
|
$
|
1,360,574
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
303,001
|
|
|
|
240,285
|
|
Interest
|
|
|
289,939
|
|
|
|
343,818
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
|
16,097
|
|
|
|
(530,474
|
)
|
Inventories
|
|
|
(27,322
|
)
|
|
|
(56,309
|
)
|
Amount due from related parties
|
|
|
(2,591,155
|
)
|
|
|
(81,600
|
)
|
Prepayments and other current assets
|
|
|
(74,585
|
)
|
|
|
10,793
|
|
Accounts payable
|
|
|
665,253
|
|
|
|
123,340
|
|
Amount due to related parties
|
|
|
108,873
|
|
|
|
(83,095
|
)
|
Deposits received
|
|
|
-
|
|
|
|
1,155
|
|
Accrued expenses and other current liabilities
|
|
|
(61,978
|
)
|
|
|
25,675
|
|
Net cash provided by operating activities
|
|
|
215,967
|
|
|
|
1,354,162
|
|
|
|
|
|
|
|
|
|
|
Cash Flows From Investing Activities
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
(373,129
|
)
|
|
|
(70,573
|
)
|
Prepayment for property and equipment acquisition
|
|
|
(218,670
|
)
|
|
|
(1,112,691
|
)
|
Net cash used in investing activities
|
|
|
(591,799
|
)
|
|
|
(1,183,264
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows From Financing Activities
|
|
|
|
|
|
|
|
|
Payments on capital lease obligation
|
|
|
(679,359
|
)
|
|
|
(539,082
|
)
|
Short-term bank loan
|
|
|
406,934
|
|
|
|
437,694
|
|
Net cash (used in) provided by financing activities
|
|
|
(272,425
|
)
|
|
|
(101,388
|
)
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate fluctuation on cash and cash equivalents
|
|
|
2,982
|
|
|
|
(7,620
|
)
|
Net decrease (increase) in cash and cash equivalents
|
|
|
(645,275
|
)
|
|
|
61,890
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of period
|
|
|
890,662
|
|
|
|
352,153
|
|
Cash and cash equivalents, ending of period
|
|
$
|
245,387
|
|
|
$
|
414,043
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
|
919
|
|
|
|
864
|
|
Cash paid for interest
|
|
|
289,939
|
|
|
|
352,406
|
|
See notes to consolidated financial statements
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 1. D
ESCRIPTION
OF
B
USINESS AND
O
RGANIZATION
JRSIS HEALTH CARE CORPORATION (the “Company”
or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The
general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States
and the State of Florida.
JRSIS HEALTH CARE LIMITED (“JHCL”),
formally named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British
Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue 50,000 shares of a single class each with
par value of $1.00 per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd
has changed its name to JRSIS HEALTH CARE LIMITED.
Runteng Medical Group Co., Ltd (“Runteng”)
is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up
to 10,000 shares with par value of HK$1 per share to its sole shareholder Ms. Yanhua Xing.
Harbin Jiarun Hospital Co., Ltd (“Jiarun”)
was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private
hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents
of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a 70% owned subsidiary of the Company.
JHCC, JHCL, Runteng and Jiarun are collectively
referred as the “Group”.
Reorganization
On December 23, 2012, in accordance with the
“Foreign Investment Enterprise Law” under the People’s Republic of China (“PRC”), Runteng and Jiarun
entered into an agreement that Runteng and the original owner of Jiarun should invest a total of RMB50,000,000 ($7,936,508), in
which Runteng and the original owner should contribute RMB35,000,000 ($5,555,556) or 70% and RMB15,000,000 ($2,380,952) or 30%
of the total capital, respectively. According to the Article of Association (Joint venture investment agreement) and the amendment
of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay RMB35,000,000 ($5,555,556) within
five years after the issuance of the joint venture business license. As of March 31, 2017, Jiarun has received $1,081,000 from
Runteng.
On March 7, 2013, JHCL acquired all 100 issued
and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng.
On June 1, 2013, Junsheng Zhang, the owner
of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In
which, the historical accumulated profit of Jiarun up to June 30, 2013 should be 100% attributed to Junsheng Zhang; the profit
generated from Jiarun after July 1, 2013 should be attributed to Runteng and Junsheng Zhang on the basis of 70% and 30%, respectively.
On July 29, 2013, the Joint Venture Investment
Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin
City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of
Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint
Venture Jiarun duration of operation is twenty years.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 1. D
ESCRIPTION
OF
B
USINESS AND
O
RGANIZATION
(C
ONTINUED
)
On October 3, 2013, Ms. Yanhua Xing transferred
23,275 JHCL shares to Mr. Junsheng Zhang, 23,225 JHCL shares to Ms. Chunlan Tang, and 1,050 JHCL shares to Mr. Weiguang Song.
On November 8, 2013, Ms. Chunlan Tang transferred
all 23,225 JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings 46,500 JHCL shares.
On December 20, 2013, a share exchange agreement
was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to
issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in
exchange for 100% of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC
a total of 50,000 shares of the ordinary share of JHCL which represents 100% of the issued and outstanding shares of JHCL. JHCL
shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or
hereafter existing, including all business and assets of any and all subsidiaries of JHCL, including 70% ownership interest in
Jiarun.
On July 8, 2014, Jiarun obtained joint venture
business license. Runteng has already completed cooperation restructuring. Up to completion of the legal structures, Jiarun are
compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.
Before and after the reorganization mentioned
above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the
other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well
as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and
rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by
Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization
transactions are considered as a series of transactions between the parties under common control and did not establish a new basis
in the assets and liabilities of the Operating Subsidiary.
During the reorganization, JHCC, JHCL, Runteng
and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization
accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests
accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements
as if the current structure existed since inception.
30% of Jiarun hospital interest held by Junsheng
Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest
in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying
to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 1, 2013, the
comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively,
from July 1, 2013.
NOTE 2. S
UMMARIES OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
The consolidated financial statements have
been prepared in accordance with the United States generally accepted accounting principles (“U.S. GAAP”).
|
B.
|
Principles
of consolidation
|
The consolidated financial statements include
the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. Non-controlling interest
is reported in the consolidated financial position within equity, separately from the Company’s equity and that net income
or loss and comprehensive income or loss are attributable to the Company’s and the non-controlling interest.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
The preparation of unaudited consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the
reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information
available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject
to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated
useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes
to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
|
D.
|
Functional
currency and foreign currency translation
|
JHCC and JHCL’s functional currency is the United States dollar
(“US$”). Runteng’s functional currency is the Hong Kong dollar (“HK$”). The functional currency of
Jiarun is the Renminbi (“RMB”).
The Company’s reporting currency is US$.
Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and
expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical
rates. Translation adjustments are reported in other comprehensive income.
|
E.
|
Concentration
of Credit Risk
|
Financial instruments that potentially subject
the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business
activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified
customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the three months ended
March 31, 2017 and 2016, no customer accounted for more than 10% of net revenue. As of March 31, 2017 and December 31, 2016, 3
and 2 customer accounted for more than 10% of net accounts receivable, respectively. For those credit sales, the Company routinely
assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance,
if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond
such allowance is limited.
|
F.
|
Cash
and cash equivalents
|
Cash and cash equivalents include all cash,
deposits in banks and other liquid investments with initial maturities of three months or less.
Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts
is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable.
The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic
conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential
for recovery is considered remote.
Inventories, consisting principally of medicines,
are stated at the lower of cost or market using the first-in, first-out method (“FIFO”). This policy requires the Company
to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company
determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products.
|
I.
|
Construction
in progress
|
Construction in progress represents the new
hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction
in progress. No depreciation is provided in respect of construction in progress.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
|
J.
|
Property
and equipment
|
Property and equipment are stated at cost.
Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized.
Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed,
the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected
in income.
Buildings and improvement
|
|
10-40 years
|
Medical equipment
|
|
5-15 years
|
Transportation instrument
|
|
5-10 years
|
Office equipment
|
|
5-10 years
|
Electronic equipment
|
|
5-10 years
|
Software
|
|
5-10 years
|
Operating lease
Leases where substantially all the rewards
and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including
scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive
income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are
recognized as expense when the achievement of the specified target is considered probable.
Capital lease
Leases which substantially transfer all of
the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities
are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present
value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their
estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and
interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements
are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.
|
L.
|
Fair
Value Measurement
|
The Company applies the provisions of ASC Subtopic
820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements
of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework
for measuring fair value and expands disclosures about fair value measurements.
Fair value is defined as the price that would
be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company
considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants
would use when pricing the asset or liability.
ASC 820 establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair
value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority
to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy
are as follows:
Level 1: Unadjusted quoted prices
in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets
that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset
or liability;
Level 3: Prices or valuation techniques
that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market
activity).
There were no transfers between level 1, level 2 or level 3 measurements
for the three months ended March 31, 2017 and 2016.
Cash and cash equivalents, accounts receivable,
accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate
fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations
also approximate carrying value as they bear interest at current market rates.
|
M.
|
Segment
and geographic information
|
The Company is operating in one segment in
accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from
customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
The Company recognizes revenue when the amount
of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been
met for each of the Company’s activities as described below.
Medicine sales
Revenue from the sale of medicine is recognized
when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine,
ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all
of which generally occur when the patient receives the medicine.
Given the nature of this revenue source of
the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale
of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.
Patient Services
In accordance with the medical licenses of
Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology,
pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.
Patient service revenue is recognized when
it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has
been provided to the patient and collection of the revenue is reasonably assured.
The Company provides services to both patients
covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient
services regardless of the coverage by social insurance.
Patients who are not covered by social insurance
are liable for the total cost of medical treatment.
|
•
|
For
out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects
payment when the patient checks out from the hospital, which is the same day the services are provided.
|
|
•
|
For
in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’
symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient
and records the payment as deposits received.
|
During the in-patient services period, the
Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The
Company records these transactions based on daily reports generated by the respective medical department. When medical services
exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.
When patients check out from the hospital,
the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients.
In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required
to be paid in full at checkout.
Patients covered by social insurance will receive
a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement
process.
Settlement process
The Company is a registered medical service
vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social
Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical
Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are
covered by social insurance agencies.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
N.
|
Revenue recognition (continued)
|
|
•
|
The
Company records patients’ information in the social insurance system at check in. The system determines the covered portion
and amounts based on the information input to the system.
|
|
•
|
At
the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from
the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have
made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.
|
|
•
|
The
Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their
review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance
agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following
the approval.
|
The Company adopts FASB ASC Topic 740, “Income
Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized
for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting
amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences
are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the
amount expected to be realized.
In July 2006, the FASB issued FIN 48 (ASC 740-10),
Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions
to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48 (ASC 740-10), tax
positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial
reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not
threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.
The application of tax laws and regulations
is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change
as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the
actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities
or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
As a result of the implementation of FIN 48
(ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards
established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity
as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated
financial statements.
Enterprise income tax is defined under the
Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises
at a rate of 25% of their taxable income.
Jiarun’s medical services have been exempt
from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with
the law of medical and health institutions, mainly provide medical services, with the “PRC Business Tax Tentative Regulations”
Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services
shall be exempt from business tax). The Company’s medical services have been exempted from business tax since March 1, 2006.
In considering the achievement of the hospital,
it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $919 and
$864 for the three months ended March 31, 2017 and 2016, respectively to support the local tax bureau’s economical obligations.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 2. S
UMMARIES
OF
S
IGNIFICANT
A
CCOUNTING
P
OLICIES
(Continued)
Basic earnings per common share is computed
by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted
earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding for the periods presented.
Q.
|
Recently accounting pronouncements
|
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842), aimed at making leasing activities more transparent and comparable. The new standard requires substantially
all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including
today’s operating leases. For public business entities, the standard is effective for fiscal years beginning after December
15, 2018, including interim periods within those fiscal years. For all other entities, the standard is effective for fiscal years
beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early application
is permitted for all entities. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated
financial condition, results of operations and cash flows.
In March 2016, the FASB issued ASU No. 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).
The amendment in this update affect entities with transactions included within the scope of Topic 606, The scope of that Topic
includes entities that enter into contracts with customers to transfer goods or services (that are an output of the entity’s
ordinary activities) in exchange for consideration. The amendments are intended to improve the operability and understandability
of the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, The amendments
in ASU 2016-10 provide more detailed guidance, including additional implementation guidance and examples in the following key areas:
1) identifying performance obligations and 2) licenses of intellectual property. In May 2016, the FASB issued ASU No. 2016-12 a
proposed Update, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, on September
30, 2015. The amendments do not change the core principles of the standard, but clarify the guidance on assessing collectability,
presenting sales taxes, measuring noncash consideration and certain transition matters. This update becomes effective concurrently
with ASU No. 2014-09. The Company is currently evaluating the effect of this new standard, including the transition method, to
determine the impact on the Company's consolidated financial position, results of operations, cash flows, or related disclosures.
In October 2016, the FASB issued Accounting
Standards Update No. 2016-16, Income Taxes – Intra-Entity Transfers of Assets Other Than Inventory (ASU 2016-16). The standard
is intended to address diversity in practice and complexity in financial reporting, particularly for intra-entity transfers of
intellectual property. ASU 2016-16 will be effective for the Company beginning with the interim periods of fiscal 2018 and requires
the modified retrospective method of adoption. Early adoption is permitted. The Company is in the process of determining timing
of adoption and assessing the impact of ASU 2016-16 on its consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash (“ASU No. 2016-18”). ASU No. 2016-18 requires that a statement
of cash flows explain the change during the period in the total of cash, cash equivalents, restricted cash and restricted cash
equivalents. Therefore, amounts generally described as restricted cash should be included with cash and cash equivalents when reconciling
the beginning of period and end of period total amounts shown on the statement of cash flows. ASU No. 2016-18 is effective for
annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company elected to early
adopt ASU No. 2016-18 for the reporting period ending December 31, 2016 and was applied retrospectively. As a result of adoption
of ASU No. 2016-18, the Company no longer presents the changes within restricted cash in the consolidated statements of cash flows.
In January 2017, the FASB issued Accounting
Standards Board Update No. 2017-01: Business Combinations (Topic 805) - Clarifying the Definition of a Business (“ASU 2017-01”).
The ASU clarifies the definition of business with the objective of adding guidance to assist entities with evaluating whether transactions
should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 will be effective for the Company’s
fiscal year beginning January 1, 2018 and subsequent interim periods with prospective application with impacts on the Company’s
consolidated financial statements that may vary depending on each specific acquisition. Early adoption is conditionally permitted.
In March 2017, the FASB issued ASU No. 2017-08,
Receivables – Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities.
Under current GAAP, entities normally amortize the premium as an adjustment of yield over the contractual life of the instrument.
This guidance shortens the amortization period for certain callable debt securities held at a premium to the earliest call date.
This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The
adoption of ASU No. 2017-08 is not expected to have a material impact on the Company’s consolidated financial statements.
We do not believe other recently issued but
not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position,
statements of operations and cash flows.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 3. Accounts Receivable, Net
|
|
March 31
|
|
|
December 31
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
|
|
Accounts receivable
|
|
$
|
3,369,665
|
|
|
$
|
3,359,619
|
|
Less: allowance for doubtful debts
|
|
|
24,307
|
|
|
|
24,119
|
|
|
|
$
|
3,345,358
|
|
|
$
|
3,335,500
|
|
The Company experienced nil bad debts during three months ended
March 31, 2017 and 2016.
NOTE 4. Inventories
At March 31, 2017 and December 31, 2016, inventories consist of
the following:
|
|
March 31
|
|
|
December 31
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
|
|
Western medicine
|
|
$
|
527,107
|
|
|
$
|
548,724
|
|
Chinese herbal medicine
|
|
|
9,905
|
|
|
|
9,113
|
|
Medical material
|
|
|
295,545
|
|
|
|
241,630
|
|
Other material
|
|
|
2,231
|
|
|
|
1,773
|
|
|
|
$
|
834,788
|
|
|
$
|
801,240
|
|
NOTE 5. Prepayment
At March 31, 2017 and December 31, 2016 prepayment consists of the
following:
|
|
March 31
|
|
|
December 31
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
|
|
Deposits on medical equipment
|
|
$
|
346,469
|
|
|
$
|
221,083
|
|
Heating fees
|
|
|
12,455
|
|
|
|
86,515
|
|
Others
|
|
|
39,414
|
|
|
|
211,124
|
|
|
|
$
|
398,338
|
|
|
$
|
518,722
|
|
NOTE 6. Property and Equipment
At March 31, 2017 and December 31, 2016, property and equipment,
at cost, consist of:
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
|
|
Transportation equipment
|
|
$
|
721,214
|
|
|
$
|
715,646
|
|
Medical equipment
|
|
|
9,698,466
|
|
|
|
9,282,026
|
|
Electrical equipment
|
|
|
1,342,080
|
|
|
|
1,310,927
|
|
Office equipment and others
|
|
|
98,586
|
|
|
|
93,283
|
|
Buildings
|
|
|
14,532,184
|
|
|
|
13,982,919
|
|
Software
|
|
|
138,094
|
|
|
|
137,028
|
|
Total fixed assets at cost
|
|
|
26,530,624
|
|
|
|
25,521,829
|
|
Accumulated depreciation
|
|
|
(2,568,047
|
)
|
|
|
(2,247,649
|
)
|
Total fixed assets, net
|
|
$
|
23,962,577
|
|
|
$
|
23,274,180
|
|
The Company recorded depreciation expense of
$303,001 and $240,285 for the three months ended March 31, 2017 and 2016, respectively.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 7. Long Term Deferred Expenses
On May 7, 2015, July 3, 2015 and October 16,
2015, Jiarun entered into three lease agreements to lease medical equipment from Hair Finance Leasing (China) Co., Ltd. (“Hair”),
a third party, for a five-year period, in which Jiarun is required to pay consulting fee to Hair for the services provided over
the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as
deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses
$65,473 and $64,967 as of March 31, 2017 and December 31, 2016. The long-term deferred expenses were $149,589 and $164,676 as of
March 31, 2017 and December 31, 2016.
The Company recorded consulting fee of $16,373
and $17,246 for the three months ended March 31, 2017 and 2016, respectively.
NOTE 8. Capital Lease Obligations and Deposit for Capital Leases
On June 5, 2013, Jiarun entered into a lease
agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related
party. The Leasing terms consist of principal plus 30 payments. Each payments will be made on an annual basis when RMB7,000,000
per payment will be paid upfront for each leasing period. The first payment was made on September, 2014. At the end of the leasing
period, a final payment will be made to settle the total leasing amount. Both parties agreed for Jiarun to pay RMB3,000,000 as
deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest
rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion
of all payments, the ownership of the lease item will be transferred to Jiarun.
The leasing agreement for our hospital building
contains the following provisions:
|
•
|
Rental
payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September.
|
|
•
|
An
option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the company.
|
|
•
|
A
guarantee by the company that the lessor will realize $nil, from selling the asset at the expiration of the lease This lease is
a capital lease because its term (30 years) exceeds 75% of the building’s estimated economic life. In addition, the present
value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295).
|
|
•
|
Accumulated
annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each
year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment
at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.
|
On September 1, 2014, October 22, 2014, March
26, 2015, May 7, 2015, July 3, 2015 and October 16, 2015, May 10, 2016, July 5, 2016, December 16, 2016 Jiarun entered into several
lease agreements to lease medical equipment and elevator from three lease finance companies, which are all third parties, for three
to five year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company was also
required to pay deposits up front, which deposits will later be used to offset against the last quarterly payment. The medical
equipment and elevator will be transferred to Jiarun upon the completion of the agreement.
These leases have been classified as capital
leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and
equipment and construction in progress.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 8. Capital Lease Obligations and Deposit for Capital Leases
(Continued)
The future minimum lease payments for annual
capital lease obligation as of March 31, 2017 are as follows:
Year
|
|
Amounts
(Unaudited)
|
|
2017
|
|
$
|
1,981,538
|
|
2018
|
|
|
1,679,089
|
|
2019
|
|
|
1,485,427
|
|
Thereafter
|
|
|
13,184,695
|
|
Total
|
|
$
|
18,330,749
|
|
The Company recorded finance lease fees of
$325,817 and $343,479 for the three months ended March 31, 2017 and 2016, respectively.
NOTE 9. Short-term Bank Loan
|
|
March 31
|
|
|
December 31
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
|
|
Short- term bank loan
|
|
$
|
420,829
|
|
|
$
|
-
|
|
As of March 31, 2017, the above bank loan was
for working capital and capital expenditure purposes. The loan was primarily obtained from Harbin Bank with interest rate of 6.09%
per annum, the contract was signed from January 19, 2017 to January 18, 2018, and the loan was received on January 24, 2017. The
interest expenses were $3,917 and $5,701 for the three months ended March 31, 2017 and 2016, respectively.
NOTE 10. Non-controlling Interests
Jiarun is the Company’s majority-owned
subsidiary which is consolidated in the Company’s financial statements with a non-controlling interest recognized. The Company
holds 70% interest of Jiarun as of March 31, 2017 and December 31, 2016.
As of March 31, 2017 and December 31, 2016,
NCI in the consolidated balance sheet was $5,557,232 and $5,052,519, respectively. For the three months ended March 31, 2017, the
comprehensive income attributable to shareholders’ equity and NCI is $1,129,904 and $504,713 respectively. For the three
months ended March 31, 2016, the comprehensive income attributable to shareholders’ equity and NCIs is $970,797 and $441,535,
respectively.
NOTE 11. Revenue
The Company’s revenue consists of medicine sales and patient
care revenue.
|
|
Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
Medicine:
|
|
|
|
|
|
|
|
|
Western medicine
|
|
$
|
2,013,797
|
|
|
$
|
1,468,236
|
|
Chinese medicine
|
|
|
427,059
|
|
|
|
387,467
|
|
Herbal medicine
|
|
|
87,219
|
|
|
|
69,972
|
|
Total medicine
|
|
$
|
2,528,075
|
|
|
$
|
1,925,675
|
|
|
|
|
|
|
|
|
|
|
Patient services:
|
|
|
|
|
|
|
|
|
Medical consulting
|
|
$
|
1,605,924
|
|
|
$
|
1,324,109
|
|
Medical treatment
|
|
|
1,370,479
|
|
|
|
1,152,292
|
|
Others
|
|
|
6,334
|
|
|
|
6,555
|
|
Total patient services
|
|
$
|
2,982,737
|
|
|
$
|
2,482,956
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,510,812
|
|
|
$
|
4,408,631
|
|
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 12. Income Tax Expense
The Company uses the asset-liability method
of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each files their taxes individually.
United States
JHCC is subject to the United States of America
Tax law at tax rate of 34%. No provision for the US federal income taxes has been made as the Company had no US taxable income
for the periods presented, and its earnings are permanently invested in PRC.
BVI
JHCL was incorporated in the BVI and, under
the current laws of the BVI, it is not subject to income tax.
Hong Kong
Runteng was incorporated in Hong Kong
and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and
income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%.
PRC
Jiarun's medical services have been exempt
from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with
the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations"
Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services
shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievement of the hospital,
it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $919 and
$864 for the three months ended March 31, 2017 and 2016, respectively to support the local tax bureau's economical obligations.
NOTE 13. Related Party Transactions
The following is the list of the related parties
to which the Group has transactions with:
(a) Junsheng Zhang, the Chairman of the Company
(b) Harbin Baiyi Real Estate Development Co.,
Ltd (“Baiyi”), owned by Junsheng Zhang
(c) Heilongjiang Dahua Medicine Wholesale Co.,
Ltd owned by Junsheng Zhang
(d) Harbin Jiarun Pharmacy Co., Limited owned
by Junsheng Zhang
(e) Heilongjiang Province Runjia Medical Equipment
Company Limited owned by Junsheng Zhang
(f) Jiarun Super Market Co., Ltd. owned by
Junsheng Zhang
(g) Harbin Qi-run pharmacy limited owned by
Junsheng Zhang
(h) Yanhua Xing and Weiguang Song, the former
shareholder of JHCL
Amount due from related parties
Amount due from related parties consisted of
the following as of the periods indicated:
|
|
March 31,
|
|
|
December 31,
|
|
Name of related parties
|
|
2017
|
|
|
2016
|
|
Harbin Baiyi Real Estate Development Co., Ltd,
|
|
$
|
4,358,193
|
|
|
$
|
1,754,987
|
|
Junsheng Zhang
|
|
|
46,500
|
|
|
|
46,500
|
|
Yanhua Xing
|
|
|
2,450
|
|
|
|
2,450
|
|
Weiguang Song
|
|
|
1,050
|
|
|
|
1,050
|
|
|
|
$
|
4,408,193
|
|
|
$
|
1,804,987
|
|
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 13. Related Party Transactions (Continued)
Amount due from Baiyi was mainly represented
the deposit for the new outpatient building which was constructed by Baiyi. The Company signed a purchase agreement with Baiyi
to acquire the first to eighth floor of a building which is under construction by Baiyi. The total amount for the purchased property
is approximately RMB63,900,000 ($9,579,894). The Company had paid a deposit of RMB10,000,000 ($1,451,136) was paid in 2016, and
paid a prepayment approximately RMB10,000,000($1,451,136) for decoration for the new outpatient building, and paid a prepayment
approximately RMB7,000,000($1,015,795) for rental payments of 2017.
Amount due from Junsheng Zhang, Yanhua Xing
and Weiguang Song, who are the prior shareholders of JHCL, was mainly for the paid-in capital to be paid.
Amount due to related parties
Amount due to related parties consisted of
the following as of the periods indicated:
|
|
March 31,
|
|
|
December 31,
|
|
Name of related parties
|
|
2017
|
|
|
2016
|
|
Harbin Jiarun Pharmacy Co., Ltd
|
|
$
|
57,005
|
|
|
$
|
-
|
|
Heilongjiang Province Runjia Medical Equipment Co., Ltd
|
|
|
14,752
|
|
|
|
18,382
|
|
Harbin Qi-run pharmacy Co., Ltd
|
|
|
-
|
|
|
|
6,947
|
|
Junsheng Zhang
|
|
|
50,000
|
|
|
|
-
|
|
|
|
$
|
121,757
|
|
|
$
|
25,329
|
|
Amount due to Harbin Jiarun Pharmacy Co.,
Ltd., Harbin Qi-run pharmacy Co., Ltd and Heilongjiang Province Runjia Medical Equipment Company Limited were mainly for the balance
for purchase of medicine and medical material from these four companies.
Amounts due to Junsheng Zhang represented the
balance paid by Mr. Zhang for the daily operation of the Company.
Related parties’ transactions
Purchase of medicine and medical material from
related parties consisted of the following for the periods indicated:
|
|
For three months ended March 31,
|
|
Name of related parties
|
|
2017
|
|
|
2016
|
|
Heilongjiang Dahua Medicine Wholesale Co., Ltd
|
|
$
|
-
|
|
|
$
|
425,928
|
|
Harbin Jiarun Pharmacy Co., Ltd
|
|
|
57,022
|
|
|
|
40,985
|
|
Heilongjiang Province Runjia Medical Equipment Co., Ltd
|
|
|
-
|
|
|
|
32,498
|
|
Harbin Qi-run pharmacy Co., Ltd
|
|
|
12,887
|
|
|
|
2,637
|
|
|
|
$
|
69,909
|
|
|
$
|
502,048
|
|
Deposits for capital leases and Capital lease obligations
On June 5, 2013, Jiarun entered into a Lease
Agreement to lease a new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang,
a related party. As of March 31, 2017, the company has balance of deposits for capital leases and capital lease obligations of
$435,341 and $13,197,472 respectively. As of December 31, 2016, the Company has balance of deposits for capital leases and capital
lease obligations of $431,980 and $13,896,989 respectively.
JRSIS HEALTH CARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AMOUNTS IN USD)
NOTE 14. Basic and Diluted Earnings Per Share
Basic net income per share is computed using
the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the
weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common
shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. The reconciliation of
the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations
is shown as follows:
|
|
Three Months Ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
Numerator:
|
|
|
|
|
|
|
|
|
Net income available to common stockholders
|
|
$
|
1,111,491
|
|
|
$
|
940,301
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Basic and diluted weighted-average number of shares outstanding
|
|
|
13,915,000
|
|
|
|
13,915,000
|
|
Net income per share:
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
$
|
0.0799
|
|
|
$
|
0.0676
|
|
NOTE 15. Contingencies and Commitment
There was no contingency as of March 31, 2017
and December 31, 2016.
NOTE 16. Subsequent Events
The Management of the Company determined that there were no reportable
subsequent events to be disclosed.
Exhibits and Financial Statement Schedules
(a) Exhibits:
The following exhibits is filed as part of this registration statement:
Exhibit
Number
|
|
Description
|
|
|
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm
|
Undertakings
The undersigned Registrant hereby undertakes:
To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:
|
(a)
|
To
include any prospectus required by Section 10(a) (3) of the Securities Act of 1933;
|
|
(b)
|
To
reflect in the prospectus any facts or events arising after the effective date of this registration statement, or most recent
post-effective amendment, which, individually or in the aggregate, represent a fundamental change in the information set forth
in this registration statement; and
|
|
(c)
|
To
include any material information with respect to the plan of distribution not previously disclosed in this registration statement
or any material change to such information in the registration statement.
|
That, for the purpose of determining any liability
under the Securities Act, each post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered herein, and the Offering of such securities at that time shall be deemed to be the initial bona fide Offering thereof.
To remove from registration by means of a post-effective
amendment any of the securities being registered hereby which remain unsold at the termination of the Offering.
Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant
to the foregoing provisions described above, or otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. Each prospectus
filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying
on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document immediately prior to such date of first use.
Signatures
Pursuant to the requirements of the Securities
Act of 1933, the Registrant has duly caused this registration statement, as amended, to be signed on its behalf by the undersigned,
thereunto duly authorized, in Orlando, Florida on June 30, 2017.
|
JRSIS HEALTH CARE
CORPORATION.
|
|
|
|
|
|
|
By:
|
/s/ Junsheng Zhang
|
|
|
|
Name: Junsheng Zhang
|
|
|
|
Title: Chairman of the board and Director
|
|
|
|
|
|
|
By:
|
/s/
Xuewei Zhang
|
|
|
|
Name: Xuewei Zhang
|
|
|
|
Title: Chief Financial Officer,
|
|
|
|
Principal Accounting
|
|
|
|
Officer and Director
|
|
|
|
|
|
|
By:
|
/s/
Lihua Sun
|
|
|
|
Name:
Lihua Sun
|
|
|
|
Title: Chief Executive Officer and Director
|
|
Pursuant to the requirements of the Securities
Act of 1933, this registration statement, as amended, has been signed by the following persons in the capacities and on the
dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Junsheng Zhang
|
|
Chairman of the board, Director
|
|
June 30, 2017
|
|
|
|
|
|
/s/ Xuewei Zhang
|
|
Chief Financial Officer and Director
|
|
June 30, 2017
|
|
|
|
|
|
/s/ Lihua Sun
|
|
Chief Executive Officer and Director
|
|
June 30, 2017
|
|
|
|
|
|
/s/ Yanhui Xing
|
|
Director
|
|
June 30, 2017
|
JRSIS Health Care (PK) (USOTC:JRSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
JRSIS Health Care (PK) (USOTC:JRSS)
Historical Stock Chart
From Jul 2023 to Jul 2024